Preprint
Article

This version is not peer-reviewed.

Lethal Viral Sepsis/Septic Shock in Getah Virus Infected Ifnar1-/- Mice

  † These authors contributed equally to this work.

Submitted:

27 August 2026

Posted:

27 August 2026

You are already at the latest version

Abstract

Getah virus (GETV) is a mosquito borne Old World alphavirus that has recently increased its geographic range, particularly in China. GETV causes rheumatic disease in horses, but in recent years its primary impact has been lethal infections in newborn piglets. Herein we characterize a lethal Ifnar1-/- mouse model of GETV, which recapitulated many of the features seen in piglets. These include lethality, high viremia, diarrhoea, and splenomegaly, with histopathological findings aligning with those seen in piglets and indicating severe, acute, multi-organ inflammatory immunopathology. RNA-Seq of spleens from GETV infected Ifnar1-/- mice and subsequent bioinformatic analyses illustrated a cytokine storm response that included robust type I interferon signatures and a pattern of cytokine/chemokine signatures indicative of viral sepsis/septic shock. Ifnar1-/- mice thus offer a framework for understanding, and a mouse model for, GETV disease in piglets. The model also indicates that lethal GETV infection in piglets ay involve viral sepsis/septic shock.

Keywords: 
;  ;  ;  ;  ;  ;  ;  

1. Introduction

Getah virus (GETV) is a mosquito transmitted alphavirus found predominantly in South and East Asia [1,2]. GETV belongs to the Semliki Forest virus antigenic complex [3], which includes the Australasian Ross River virus (RRV) [4] and the globally distributed chikungunya virus (CHIKV) [5]. The geographic range of GETV is growing, in particular in China [2,6], with GETV contamination of a live porcine reproductive and respiratory syndrome virus vaccine potentially contributing [7]. Serosurveys suggest a range of wild and domestic ungulates are the primary targets of infection by GETV [8]. The virus has caused disease outbreaks, leading to significant economic losses, primarily in horses and pigs [1,9,10,11,12]. Although human infection with GETV is frequently claimed, the contention arises from a small number of primary references that are somewhat dated [13,14,15,16], with no recent studies emerging that use modern, and substantially more reliable, serodiagnostic methodologies [17]. To the best of our knowledge, a confirmed clinical GETV infection in humans has not been reported. Cross-reactivity with other serologically related alphaviruses can also provide false seropositive results for GETV. For instance, historical serosurveys did suggest GETV circulates in Australia; however, a series of analyses indicated that this is likely not the case, with serosurveys probably compromised by strong cross-reactivity of RRV immune sera with GETV [18].
GETV belongs to a group of Old World alphaviruses, such as RRV and CHIKV, where human symptomatic infections are usually associated with a spectrum of rheumatic disease manifestations, primarily fever, rash, myalgia and polyarthritis/polyarthralgia [4]. Symptomatic GETV infections in horses are also associated with fever, rash, hind limb oedema (mainly fetlock), as well as lymph node swelling lasting for 1–2 weeks [19]. GETV infection, like RRV [20], can affect racehorse performance, with a whole-virus formalin-inactivated combined vaccine for Japanese encephalitis virus (JEV) and GETV (JE/GETV vaccine) commercially available in Japan (Nisseiken Co., Ltd., Tokyo) for use in racehorses [3,21,22,23].
In contrast to GETV infection in horses, infection in neonatal and suckling piglets is often associated with mortality, preceded by a series of symptoms including fever, loss of appetite, diarrhoea, ataxia and cyanosis [11,24,25]. Increased virulence with 100% mortality [26,27] has recently been reported, and was associated primarily with genotype III viruses [6,25,28,29]. Fatal infections are characterized by a constellation of histopathological lesions across multiple organ systems. In lungs GETV infection caused widened alveolar septa, epithelial desquamation, alveolar-wall thickening, and intra-alveolar hemorrhage, with leukocyte infiltration [11,24,27,30]. In spleen, hemorrhagic splenitis was observed, characterized by reduced white-pulp volume, hemorrhage, and inflammatory-cell infiltration [11]. In liver, leukocyte infiltration, hepatocellular degeneration and hemorrhage was reported [11]. In brain, mild neuronal degeneration and vascular inflammatory-cell infiltration was seen [11]. In kidneys, histopathology included inflammatory infiltrates with erythrocyte extravasation, glomerular vasodilation, tubular epithelial swelling, and irregular tubular lumina [11]. For intestines, villous epithelial injury with inflammatory lesions was reported by several groups [11,27,30]. These findings indicate an acute, severe multi-organ inflammatory immunopathology.
The GETV viremia levels in adult pigs are relatively low, peaking at ≈4 log10CCID50/mL [31], similar to adult wild-type mice [3]. In newborn piglets the blood virus load would appear to be much higher, up to ≈7 log10 viral copies per ml [30], and (as noted above) is often associated with mortality. Paralysis and mortality are well described features of alphavirus infections in neonatal mice, including GETV infections, with a permeable blood brain barrier often leading to brain infections and paralysis [32,33]. A key reason why neonates readily succumb to alphaviral infections is their immature/defective type I IFN responses [32,34,35,36,37]. The early and rapid innate type I IFN response represents a key mechanism that protects adult mice from excessive viremias and mortality [38,39,40,41,42,43].
A range of efforts are underway to develop new GETV vaccines [22,44,45], antivirals [46,47], and diagnostics [48,49]. We thus sought herein to characterize a mouse model of GETV infection that recapitulates the lethal infection seen in young piglets. The use of neonatal piglets and neonatal mice for evaluating new interventions is relatively expensive, ethically challenging and often inconvenient, as pregnant animals give birth to variable numbers of offspring, often with timing that is difficult to synchronise. We therefore characterized adult, type I IFN receptor 1 knock-out (Ifnar1-/-) mice as a potential model of lethal GETV infection, as these animals recapitulate the defective type I IFN responses often observed in neonates [32,34,35,36,37]. They also represent a widely available and widely used, well characterized, genetically modified mouse strain [42]. Cells in Ifnar1-/- mice are unable to respond to cytokine signalling mediated by IFNβ and a series of IFNαs [50], with these latter type I IFNs strongly induced by alphavirus infections in wild-type mice [43,51]. Infection of Ifnar1-/- mice (or other type I IFN response deficient mice) with most pathogenic alphaviruses, including GETV [52,53], generally results in high viremias, a surge in pro-inflammatory cytokines, and mortality within a few days [39,40,41,42,54]. To provide a detailed characterization of the cytokine responses, we describe herein a RNA-Seq analysis of the spleens of GETV infected Ifnar1-/- mice. Although RNA-Seq data has been reported for orthoflavivirus infected Ifnar1-/- mice [55,56], to the best of our knowledge, RNA-Seq data from alphavirus infected Ifnar1-/- mice has not previously been reported, and revealed surprisingly robust type I IFN responses despite the absence of a functional type I IFN receptor.

2. Materials and Methods

2.1. Ethics and Regulatory Statement

Mouse work was conducted in accordance with the “Australian code for the care and use of animals for scientific purposes” as defined by the National Health and Medical Research Council of Australia. Mouse work was approved by the QIMR Berghofer Animal Ethics Committee (P3746, A2108-612). Breeding and use of GMO mice were approved by the QIMRB Safety Committee under a Notifiable Low Risk Dealing (NLRD) Identifier: GTSC_075_2025: NLRD1.1(a). Research with live GETV was approved under the Queensland Biosecurity Act 2014, Scientific Research (prohibited matter)—Permit no. PRID000907. This legislation declares GETV to be an exotic virus [18], with specific containment and reporting procedures required to work with this virus in Queensland. All research was approved by the QIMR Berghofer Institutional Safety Committee.

2.2. The GETV Isolate, Culture and Titration

GETVMM2021 (GenBank MN849355) was obtained from the Doherty Virus collection, located at QIMR Berghofer. GETVMM2021 is the original 1955 prototype genotype I GETV isolate from Malaysia imported into Australia in the 1960s [18]. The virus was propagated in C6/36 cells and the titre determined using CCID50 assays as described [22].

2.3. Mouse Infection and Monitoring

Ifnar1-/- mice on a C57BL/6J background [57] were originally provided by Dr P. Hertzog (Monash University, Melbourne, Australia) and were bred in-house at QIMRB [52,58]. These mice do not express a functional Ifnar1 protein and are thus unable to signal via the IFNα/β receptor. Details of mouse agistment conditions have been described previously [22], with sibling male mice housed together and male mice from different litters housed separately. Mice were injected subcutaneously on the top/side of each hind foot [41] with 40 µL per foot (see [3] for details), with either tissue culture supernatant containing infectious GETV or with heat inactivated (56 °C for 1 h) tissue culture supernatant containing inactivated GETV (Control). Mice were weighed and monitored daily [59] and were euthanized using CO2 when ethically defined endpoints were reached. Weight loss reaching or approaching 20% was the main criterion triggering the ethical requirement for euthanasia.

2.4. Histology

Histology was undertaken as described [22,60] and was undertaken using a cohort of female mice. In brief, tissues were fixed in 10% formalin and embedded in paraffin (Sigma-Aldrich, Missouri, USA). Sections were stained with hematoxylin and eosin (H&E) (Sigma-Aldrich). Slides were scanned using Aperio AT Turbo (Aperio, Vista, CA, USA) and were viewed using Aperio ImageScope (v12.4.0.5043). Scanned slides were examined by a European board-certified veterinary pathologist using QuPath software v0.5.1 [61].

2.5. RNA-Seq and Bioinformatics

RNA-Seq was undertaken as described [62,63,64] using a cohort of male mice. In brief, spleens were cut open and placed in RNALater (Invitrogen) and RNA extracted using TRIzol (Invitrogen). The RNA Integrity Number for one sample was too low for further processing leaving GETV infected n = 5 and Controls n = 4. Extracted RNA cDNA libraries were generated using Illumina TruSeq Stranded mRNA library prep kit (polyA enrichment). Sequencing was undertaken using the Illumina Nextseq 2000 platform to generate 75 bp paired end reads. STAR aligner was used to align the RNA-Seq reads to a combined mouse (GRCm39, version M27) and GETVMM2021 (GenBank MN849355) reference genome. A standard filter of 0.25 counts per million was applied. Differentially expressed genes (DEGs) were identified using EdgeR using a false discovery rate (q) cut-off of q < 0.01 and fold change > 2 (i.e., log2 > 1). These latter filters were applied, as described previously for CHIKV infections [51,57], to reduce DEG numbers to approach the range “for best results” from Ingenuity Pathway Analysis (IPA) [65]. The latter was performed using IPA, v84978992 (QIAGEN) [64].

2.6. Statistics

Mouse data: the t-test (with Welch’s correction) was used if the difference in variances was <4 fold. The t test significance and variance were determined using Microsoft Excel. Otherwise, the non-parametric Kolmogorov-Smirnov exact test was performed using GraphPad Prism 10.

3. Results

3.1. GETV Virus Infection of Ifnar1-/- Mice, Weight Loss, Viremia and Haematocrit

GETV infection of adult male Ifnar1-/- mice resulted in rapid weight loss, which reached or approached the ethically defined end point for euthanasia of ≈20% weight loss within 4 days (Figure 1a). The viremias rose very rapidly in GETV infected mice reaching 8–9 log10CCID50/mL of serum on days 2–4 post infection (Figure 1b). Similar data were obtained for adult female Ifnar1-/- mice (Figure S1).
Increases in haematocrits have previously been reported in mice defective for type I IFN responses infected with CHIKV [40]. Increases in haematocrits are also well established for dengue virus infections in Ifnar1-/- mice [66] and in humans [67]. To the best of our knowledge, haematocrit levels have not been reported for lethal GETV infections in piglets. Haematocrit levels in GETV infected Ifnar1-/- mice were thus assessed when they had reached ethically defined endpoints. Haematocrit levels were quite variable, with no overall significant differences (n = 5 per group) emerging. However, an increased haematocrit was seen in 3/5 animals euthanized on day 3 or 4, with this selected subset (n = 3) significantly higher than Controls (n = 5) (Figure 1c). An increasing haematocrit is a sign of haemo-concentration that can be due to diarrhoea (see below), and can also be a feature of shock or pre-shock states [68], with cytokine storms (see below) able to induce vascular permeability [69,70,71]. These 3 mice also showed elevated levels of endogenous serum lactate dehydrogenase (Figure S2), a non-specific marker of general tissue damage and also an indicator of disease severity in sepsis patients [72].

3.2. GETV Virus Infection in Ifnar1-/- Mice Was Associated with Overt Diarrhoea

GETV infected mice that had reached the ethically defined endpoints on day 3 or 4 post infection were euthanized (Figure 1a,b), and at the same time mice that had been inoculated with heat inactivated GETV (Controls) were also euthanized. Intestines were dissected out and photographed (Figure 2). Consistent with the animal house observations of overt diarrhoea in the GETV infected mice, only a limited amount of faecal matter was visible in the intestines of these animals. In contrast, Control animals showed normal levels of faecal matter in the small intestine, cecum and colon (Figure 2).
Diarrhoea is a non-specific sign/symptom, but is well documented in GETV infected piglets [6,11,26,27,28,30]. Diarrhoea can also occur during acute infections with other alphaviruses [73], especially in infants and young children [4,74,75].

3.3. Splenomegaly in GETV Infected Ifnar1-/- Mice

Spleens from GETV infected Ifnar1-/- mice (euthanized when they reached ethically defined endpoints on days 3 or 4) and Control mice (euthanized at the same time points) were fixed, embedded in paraffin and longitudinal median sections stained using H&E. Stained sections were scanned (Figure 3a) and areas determined using Aperio ImageScope (Figure 3b). Overt and significant spleen enlargement (splenomegaly) was seen in GETV infected animals (Figure 3). Splenic enlargement was reported for piglets experimentally infected with GETV [11]. Reports of splenomegaly associated with infections by other Old World alphaviruses are, to the best of our knowledge, limited to mayaro virus infection of weanling Balb/c mice [76]. Splenomegaly is, however, a feature of dengue virus infections in children [77].

3.4. Histopathological Findings in GETV Infected Mice

Tissues from euthanized GETV infected and Control mice were fixed, embedded in paraffin, sections stained with H&E and examined by a European board-certified veterinary pathologist.
Lungs. The lungs of GETV infected Ifnar1-/- mice show (i) capillary damage with leakage (Figure 4a, white oval), (ii) leukostasis (Figure 4a, white arrowheads), (iii) fibrinous pleurisy (Figure 4a, black rectangle), and fibrin in alveoli (Figure 4a, black arrow). Although not specifically mentioned, these features do align with histopathology seen in GETV infected piglets [11,24,27,30]; (i) haemorrhage and leukocyte infiltration in alveolar cavities, aligns with damaged capillaries (Figure 4a, white oval) allowing blood into alveoli), (ii) widening septa and wall thickening, aligns with inflammatory cells (Figure 4a, white arrowheads) causing swelling and wall thickening, and (iii) epithelial desquamation (sloughing of damaged cells), can cause leakage of clotting factors (Figure 4a, black arrow).
Spleen. In the T cell areas and marginal zone of the white pulp of the spleen, areas of focal necrosis were observed (Figure 4b, white ovals), with a diffuse increase in the number of cells undergoing degeneration (perinuclear haloing) (Figure 4b, arrow). Similar features were seen in lymph nodes. Descriptions of histopathological lesions in spleens of GETV infected piglets are limited [27], although one study provided a diagnosis of haemorrhagic splenitis; reduced white-pulp volume, haemorrhage and inflammatory cell infiltration on day 4 post infection [11]. Cellular degeneration (necrosis and apoptosis) generally occurs before white pulp atrophy, haemorrhage and inflammatory cell infiltration, with the latter associated with the clearance of dead cells. So splenic manifestations would appear to be more advanced in piglets than in these mice, although they may reflect the same underlying disease processes.
Liver. The liver of GETV infected Ifnar1-/- mice displayed intravascular leukocytosis (Figure 4c, white ovals) and leukostasis (Figure 4c, white arrowheads); compare with blood vessels in Control liver (Figure 4c, Control). Focal infiltration of leukocytes in sinusoidal spaces (blood vessels) and inflammatory cell infiltration in central veins [11], was reported for GETV infected piglets and aligns well with the observations in mice. However, the hepatocellular degeneration and haemorrhage reported in piglets [11] was not a finding in mice.
Brain. Focal mild inflammatory cells were present in the meninges of GETV infected Ifnar1-/- mice (Figure 4d, white arrowheads). This aligns well with the mild vascular inflammatory cell infiltrate reported for GETV infected piglets [11]. However, the mild neuron degeneration seen in piglets [11] was not a significant observation in GETV-infectedmice.
No significant GETV infection-associated histopathological lesions were identified in kidneys, intestine or hind feet [40,78]. In summary, histopathological lesion in mice thus appear to be less severe overall than those seen in piglets. Nevertheless, histopathology from both species describe severe, acute, multi-organ inflammatory immunopathology.

3.5. RNA-Seq and Bioinformatic Analyses of Spleens from GETV Infected vs. Control Ifnar1-/- Mice

At euthanasia spleens were harvested from GETV infected mice and at the same time (day 3 or 4) spleens were also harvested from mice inoculated with heat-inactivated GETV (Controls). Spleens were analysed by RNA-Seq and the full data set is provided in Table S1. Viral read counts illustrated the presence of GETV RNA in the infected mice, with no viral read counts detected in the Controls (Figure 5a). The viral reads in infected mice may reflect virus in blood rather than infection of spleen cells as animals were euthanized at or close to peak viremia (Figure 1b). A Principal Component Analysis (PCA) plot shows a clear separation between infected and control mice (Figure 5b), and a volcano plot illustrates robust and significant changes in gene expression (Figure 5c).
Differentially expressed genes (DEGs) (GETV infected vs. Control; n = 2383, fold change > 2, q < 0.01) were analysed by Ingenuity Pathway Analysis (IPA), with Canonical pathways and Upstream Regulators (USRs) representing primary outputs from such analyses. The latter outputs provide much higher levels of cross-species concordance than comparisons of DEGs [79,80], and were thus the focus of our current reporting. Canonical and USR pathways are summarized in Figure 5d (full data set in Table S1). Innate sensing pathways feature prominently, as might be expected for an alphavirus infection [38,41,51,81]. The poly I:C, TLR3 and TLR7 annotations likely reflect detection of viral RNA. The TLR4 annotation may reflect detection of cell debris arising from virus-induced cytopathic effects (CPE) [82], although gene induction profiles for TLR4 and the other TLRs can overlap [83]. MyD88 is a key signal transduction adaptor for TLR signalling. The STING annotation may reflect detection of mitochondrial DNA from cells undergoing CPE [84].
Perhaps surprisingly for Ifnar-/- mice, robust type I IFN signatures were evident (Figure 5d), with upregulation of many IFNα mRNAs also seen (Figure S3). These type I IFN responses and signatures have also been reported in wild-type mice and humans and are believed to be central for controlling acute alphavirus infections [38,41,51,81,85,86,87]. Alphavirus infections in Ifnar-/- mice generally show high viremias and these mice generally succumb to acute infection [41,42]. This is also the case for GETV infection of Ifnar-/- mice (Figure 1a) [52], despite these robust type I IFN signatures (see Discussion).

3.6. mRNA Expression Signatures in Spleens of GETV Infected Ifnar1-/- Mice Indicate Viral Sepsis and/or Viral Septic Shock

Viral sepsis and septic shock are well described for dengue and COVID-19 and are also recognized for a number of other viral infections [88,89,90,91]. The top Canonical pathway and the top cytokine USRs (Figure 5d) suggest Ifnar1-/- mice infected with GETV succumb to viral sepsis and/or viral septic shock. TNF, IL-1 and IFNγ (Figure 5d, Cytokine storm) are considered the archetypal shock mediators [91,92,93,94], with IFNγ also recognized as a marker of hyper-inflammation [95]. Neutrophil degranulation (Figure 5d) is also a key feature of sepsis [96]. CHIKV infections can cause viral sepsis and septic shock in humans [97] and in Irf3/7-/- mice [40], although these are generally considered rare disease manifestations for Old World alphavirus infections [4,5]. A full literature search was thus undertaken, which illustrated that the majority of the cytokine/chemokines identified as top scoring USRs, have been reported to be elevated during sepsis and/or septic shock (Table 1). The bacterial sepsis and septic shock cytokine/chemokine literature was included as this is considerably larger and more expansive than the viral sepsis and septic shock literature, with the two (bacterial and viral) showing considerable overlap in upregulated cytokine/chemokine responses (Table 1).
In summary, RNA-Seq of spleens from euthanized GETV infected and Control Ifnar1-/- mice, and ensuing bioinformatic analyses, revealed a pattern of cytokine/chemokine signatures that illustrated a cytokine storm response (Figure 5d), which was strongly indicative of viral sepsis and viral septic shock (Table 1).

4. Discussion

The studies reported herein illustrate a series of parallels between GETV infected Ifnar1-/- mice and GETV infected piglets. As reported previously [52], the high viremias and lethality seen in GETV infected Ifnar1-/- mice (Figure 1a,c), recapitulates the high viremias (up to 7 logs per ml [30]) and lethality seen in GETV infected piglets. Splenomegaly (Figure 3) has also been reported for GETV infections in piglets [11]. The diarrhoea observed in GETV infected Ifnar1-/- mice (Figure 2) is also seen in GETV infected piglets [6,11,26,27,28,30], with diarrhoea a common non-specific symptom that can occur during inter alia sepsis and septic shock [68]. Overall the histopathological findings indicate that GETV infection-associated lesions are more severe in piglets than in Ifnar1-/- mice, which may reflect the evolutionary adaptation of GETV preferentially to infect ungulates and/or may arise from Australian ethical requirements to euthanize mice before they show unacceptable levels of overt disease. Other factors may also contribute to the lower disease severity observed in Ifnar1-/- mice. Detailed histopathology for several organs in GETV infected piglets relies on one reference [11], with all the reported histopathology (see Introduction) involving contemporary genotype III viruses, whereas the MM2021 strain used herein is genotype I. There are also inherent limitations in comparing histopathology in two distantly related mammalian species; mice (superorder Euarchontoglires, to which humans also belong) and pigs (superorder Laurasiatheria). Nevertheless, histopathological findings for the two species are both indicative of a severe, acute, systemic, multi-organ, inflammatory pathology [206,207,208]. The latter, and especially white pulp injury and focal lymphoid death in spleen (Figure 4b), are all consistent with severe sepsis and/or septic shock [209,210].
The RNA-Seq and bioinformatic analyses of cytokine and chemokine responses in GETV infected Ifnar1-/- mice show cytokine storm signatures that further support a diagnosis of sepsis/septic shock (Table 1). To the best of our knowledge, neither protein- or RNA-based cytokine/chemokine studies have been published for lethal GETV infections in piglets. Only RNA-Seq analyses of in vitro infections of a porcine cell line have been reported [211]. A diagnosis of viral sepsis and/or septic shock have also not (to the best of our knowledge) been formally enunciated or established for GETV infected piglets in the publicly available literature. Nevertheless, clinical observations associated with lethal GETV infections in piglets [29,30,212] are consistent with viral sepsis and/or septic shock. For instance, cyanosis is well described for piglets with lethal GETV infections [25,27,213], and cyanosis is a late stage sign of advanced sepsis or septic shock [68]. Unfortunately, cyanosis is difficult to observe in black mice, which were used herein; specifically Ifnar1-/- mice on a C57BL/6J background [57].
Conceivably, GETV infection leads to bacterial or endotoxin translocation from the gut into the circulation (with ensuing endotoxemia-mediated sepsis/shock). To the best of our knowledge, this has never been reported for alphavirus infections, although intestinal damage has been observed by histology for CHIKV infections [214]. No gut histopathology was observed in our study, with diarrhoea often associated with dysregulated ion and water transport in the gut, rather than histologically detectable mucosal injury [215]. Instead, sepsis-associated cytokines can mediate such dysregulated transport in gut epithelial cells [216,217,218], which can then lead to diarrhoea.
The type I IFN receptor is involved in the promotion of bacterial sepsis/septic shock in a number of settings [189,219,220,221]. A similar role for the type I IFN receptor in promoting viral sepsis/shock has not been reported, consistent with the key anti-viral (including anti-alphaviral [38]) role played by type I IFN responses. Infections in mice deficient in type I IFN responses often result in high viremias and acute lethality [42], with the data presented herein supporting previous reports [40,222] that this can lead to viral sepsis/septic shock.
A perhaps surprising observation is the robust type I IFN responses observed in GETV infected Ifnar1-/- mouse spleens (Figure 5d, Figure S3). Why do these responses fail to protect the Ifnar1-/- mice from the overwhelming lethal viremia? Cells infected with GETV would be able to generate type I IFN responses via cytoplasmic sensors [43], although these intracellular responses are generally insufficiently fast, robust and/or effective to achieve substantial curtailment of alphaviral replication already initiated in the infected cells [223,224]. Leukocytes can also generate type I IFN responses after TLR-mediated detection of cellular debris and viral RNA released from cells undergoing CPE [225,226]. The type I IFN receptor mediates a rapid feed-forward loop that rapidly amplifies secretion of IFNαs [227,228], a mechanism clearly absent in Ifnar1-/- mice. Nevertheless, consistent with the data presented in Figure S3, IFNαs can still be secreted in vivo in the absence of the type I IFN receptor [229,230,231]. However, the key issue in Ifnar1-/- mice is that circulating IFNβ and IFNαs, in the absence of the type I IFN receptor, are unable to protect uninfected cells from rapidly spreading viral infections via induction of anti-viral states [232,233]. Thus, even though robust type I IFN responses are seen in whole spleen tissues, GETV (and other viruses) can spread rapidly in Ifnar1-/- mice because IFNα/β, without the type I IFN receptor, is unable to induce anti-viral states in uninfected cells [39,234].
Understanding the aforementioned mechanisms may have relevance for the field of oncolytic virotherapy, with GETV being considered as a potential treatment for glioblastoma [235]. Viral infection and killing of cancer cells relies on antiviral resistance being induced in healthy cells (via infection-induced circulating IFNα/β), whereas antiviral resistance would need to be less effectively induced in cancer cells [236] to allow the spread of viral infection through the tumour. Thus, predicting effective GETV virotherapy might focus on tumours that are unable to generate an antiviral state after IFNα exposure. Type I IFN responses induced within GETV-infected glioblastoma cells are perhaps less informative for selecting patients with tumours that might be susceptible to virotherapy [209].
Perhaps perplexing is that genetically identical mice, all inoculated with essentially the same dose of GETV, can show such large mouse-to-mouse variation, for instance, with respect to viral loads (≈2 logs, Figure 1b, Figure 4a and Figure S1), haematocrit changes (Figure 1c) and serum lactate dehydrogenases levels (Figure S2). Age differences between adult mice (beyond 6–8 weeks) may (8 vs. 20 weeks of age [237]) or may not (6 to 12 weeks of age [60]) have a significant influence on alphavirus infection and/or disease in mice. However, infection outcomes for co-caged isogenic mice can actually differ because of social and behaviour factors. Both male and female mice establish social hierarchies [238], wherein subordinate status has been associated with higher basal cortisol [239], which can affect host resistance to viral infection [240,241,242]. In addition, mice held at standard animal house temperatures suffer from a degree of cold stress that can exacerbate viral infections [59,242,243,244]. Huddling can elevate body temperatures [245,246], with the centre of the huddle potentially providing a thermal advantage [246,247]. Social hierarchies are also established in piglets early post-partum, with a higher position improving suckling and weight gain [248]. Enhanced early piglet growth has been shown to positively influence innate immunity [249].
In summary, we characterize herein GETV infection in Ifnar1-/- mice and propose this represents a suitable model of GETV infection in piglets. However, the key finding of viral sepsis/septic shock has yet to be established for lethal GETV infections in piglets, although disease manifestations and histopathology in piglets are consistent with such a diagnosis.

5. Conclusions

GETV infections in Ifnar1-/- mice recapitulate many of the features seen for GETV infections of piglets. Infections with other Old World alphavirus are primarily associated with self-resolving inflammatory arthropathy [4], which is not recapitulated in Ifnar1-/- mouse models [250]. Even if sepsis/septic shock is confirmed in lethal GETV infection of piglets, treatment might be viewed as difficult and impractical. Nevertheless, supportive care and intravenous (or intra osseous) fluids may help, given its effective use for treating dengue shock in children [210]. Vaccination [3,22] of sows is also an option, with protective antibodies [3,23] transferred to the neonates via the colostrum.

Supplementary Materials

The following supporting information can be downloaded at the website of this paper posted on Preprints.org, Figure S1: Infection of female Ifnar1-/- mice with GETV; Figure S2 Endogenous serum lactate dehydrogenase; Figure S3. IFNα subtypes and related genes. Table S1: Full RNA-Seq and bioinformatic data set.

Author Contributions

Conceptualization, Cameron Bishop and Andreas Suhrbier; Data curation, Cameron Bishop and Andreas Suhrbier; Formal analysis, Cameron Bishop, Thibaut Larcher and Andreas Suhrbier; Funding acquisition, Andreas Suhrbier; Investigation, Cameron Bishop, Bing Tang and Thibaut Larcher; Methodology, Cameron Bishop and Andreas Suhrbier; Project administration, Andreas Suhrbier; Resources, Daniel Rawle and Andreas Suhrbier; Software, Cameron Bishop; Supervision, Daniel Rawle and Andreas Suhrbier; Validation, Cameron Bishop; Visualization, Thibaut Larcher and Andreas Suhrbier; Writing—original draft, Thibaut Larcher and Andreas Suhrbier; Writing—review & editing, Cameron Bishop, Bing Tang and Andreas Suhrbier.

Funding

This research was funded by National Health and Medical Research Council (NHMRC) of Australia, Investigator grant awarded to A.S. (APP1173880).

Institutional Review Board Statement

All mouse work was conducted in accordance with the ‘Australian code for the care and use of animals for scientific purposes’ as defined by the National Health and Medical Research Council of Australia. Mouse work was approved by the QIMR Berghofer Animal Ethics Committee (P3746, A2108-612). Breeding and use of GMO mice were approved by the QIMRB Safety Committee under a Notifiable Low Risk Dealing (NLRD) Identifier: GTSC_075_2025: NLRD1.1(a).

Acknowledgments

The authors thank the QIMR Berghofer MRI animal house staff for mouse breeding and agistment; and Dr Gunter Hartel (Group Leader Statistics Group) for assistance with statistics.

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Abbreviations

The following abbreviations are used in this manuscript:
GETV getah virus
Ifn/IFN interferon
Ifnar1 interferon alpha receptor subunit 1 (gene)
CHIKV chikungunya virus
COVID-19 Coronavirus disease of 2019
RNA-Seq ribonucleic acid sequencing
USR upstream regulator
mRNA messenger ribonucleic acid
DEGs differentially expressed genes
CCID50 50% cell culture infectivity dose
TLR Toll like receptor
CPE cytopathic effect
H&E hematoxylin and eosin

References

  1. Li, B.; Wang, H.; Liang, G. Getah Virus (Alphavirus): An Emerging, Spreading Zoonotic Virus. Pathogens 2022, 11, 945. [Google Scholar] [CrossRef] [PubMed]
  2. Shen, J.; Liu, S.; Liu, S.; Shen, S.; Lei, M.; Xu, Q.; Li, W.; He, Q.; Xu, X.; Cai, X. Genomic surveillance and evolution of Getah virus. Virus Evol. 2025, 11, veaf007. [Google Scholar] [CrossRef] [PubMed]
  3. Nguyen, W.; Nakayama, E.; Yan, K.; Tang, B.; Le, T.T.; Liu, L.; Cooper, T.H.; Hayball, J.D.; Faddy, H.M.; Warrilow, D.; et al. Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models. Vaccines 2020, 8, 209. [Google Scholar] [CrossRef] [PubMed]
  4. Suhrbier, A.; Jaffar-Bandjee, M.-C.; Gasque, P. Arthritogenic alphaviruses—An overview. Nat. Rev. Rheumatol. 2012, 8, 420–429. [Google Scholar] [CrossRef] [PubMed]
  5. Suhrbier, A. Rheumatic manifestations of chikungunya: Emerging concepts and interventions. Nat. Rev. Rheumatol. 2019, 15, 597–611. [Google Scholar] [CrossRef] [PubMed]
  6. Yu, L.; Chen, L. The epidemiological and evolutionary dynamics of Getah virus in China. Vet. Vaccine 2026, 5, 100172. [Google Scholar] [CrossRef]
  7. Chu, P.-P.; Chen, S.-N.; Zhou, X.; Wei, Z.-Z.; Zhai, S.-L. Getah Virus: A New Contaminant in Veterinary Vaccines. Vet. Sci. 2025, 12, 82. [Google Scholar] [CrossRef] [PubMed]
  8. Irekeola, A.A.; Shueb, R.H. Global seroprevalence and distribution of Getah virus in domestic and wild animals: A systematic review and meta-analysis. Vet. World 2025, 18, 3464–3475. [Google Scholar] [CrossRef] [PubMed]
  9. Ochi, A.; Bannai, H.; Aonuma, H.; Kanuka, H.; Uchida-Fujii, E.; Kinoshita, Y.; Ohta, M.; Kambayashi, Y.; Tsujimura, K.; Ueno, T.; et al. Surveillance of Getah virus in mosquitoes and racehorses from 2016 to 2019 at a training center in Ibaraki Prefecture, Japan, a site of several previous Getah virus outbreaks. Arch. Virol. 2023, 168, 35. [Google Scholar] [CrossRef] [PubMed]
  10. Zhong, D.; Zheng, J.; Ma, Z.; Wang, Y.; Wei, J. Rapid Detection of Getah Virus Antibodies in Horses Using a Recombinant E2 Protein-Based Immunochromatographic Strip. Animals 2024, 14, 2309. [Google Scholar] [CrossRef] [PubMed]
  11. Lan, J.; Fang, M.; Duan, L.; Liu, Z.; Wang, G.; Wu, Q.; Fan, K.; Huang, D.; Ye, Y.; Wan, G. Novel porcine getah virus from diarrheal piglets in Jiangxi province, China: Prevalence, genome sequence, and pathogenicity. Animals 2024, 14, 2980. [Google Scholar] [CrossRef] [PubMed]
  12. Qiu, Z.; Zhang, D.; Fan, Q.; Hu, Z.; Xie, H.; Li, N.; Xiao, P. Getah Virus in Review: An Emerging Zoonotic Arbovirus. Transbound. Emerg. Dis. 2026, 2026, 9245726. [Google Scholar] [CrossRef] [PubMed]
  13. Kanamitsu, M.; Taniguchi, K.; Urasawa, S.; Ogata, T.; Wada, Y.; Wada, Y.; Saroso, J.S. Geographic distribution of arbovirus antibodies in indigenous human populations in the Indo-Australian archipelago. Am. J. Trop. Med. Hyg. 1979, 28, 351–363. [Google Scholar] [CrossRef] [PubMed]
  14. Marchette, N.J.; Rudnick, A.; Garcia, R. Alphaviruses in Peninsular Malaysia: II. Serological evidence of human infection. Southeast Asian J. Trop. Med. Public Health 1980, 11, 14–23. [Google Scholar] [PubMed]
  15. Li, X.; Qiu, F.; Yang, H.; Rao, Y.; Calisher, C.H. Isolation of Getah virus from mosquitoes collected on Hainan island, China, and results of a serosurvey. Southeast Asian J. Trop. Med. Public Health 1992, 23, 730–734. [Google Scholar] [PubMed]
  16. Lvov, S.D.; Gromashevsky, V.L.; Andreev, V.P.; Skvortsova, T.M.; Kondrashina, N.G.; Morozova, T.N.; Avershin, A.D.; Aristova, V.A.; Dmitriev, G.A.; Kandaurov, Y.K.; et al. Natural foci of arboviruses in far northern latitudes of Eurasia. Arch. Virol. 1990, 267–275. [Google Scholar] [CrossRef]
  17. Farmer, J.F.; Suhrbier, A. Interpreting paired serology for Ross River virus and Barmah Forest virus diseases. Aust. J. Gen. Pract. 2019, 48, 645–649. [Google Scholar] [CrossRef] [PubMed]
  18. Rawle, D.J.; Nguyen, W.; Dumenil, T.; Parry, R.; Warrilow, D.; Tang, B.; Le, T.T.; Slonchak, A.; Khromykh, A.A.; Lutzky, V.P.; et al. Sequencing of Historical Isolates, K-mer Mining and High Serological Cross-Reactivity with Ross River Virus Argue against the Presence of Getah Virus in Australia. Pathogens 2020, 9, 848. [Google Scholar] [CrossRef] [PubMed]
  19. Fukunaga, Y.; Kumanomido, T.; Kamada, M. Getah virus as an equine pathogen. Vet. Clin. N. Am. Equine Pract. 2000, 16, 605–617. [Google Scholar] [CrossRef] [PubMed]
  20. Barton, A.J.; Bielefeldt-Ohmann, H. Clinical Presentation, Progression, and Management of Five Cases of Ross River Virus Infection in Performance Horses Located in Southeast Queensland: A Longitudinal Case Series. J. Equine Vet. Sci. 2017, 51, 34–40. [Google Scholar] [CrossRef]
  21. Nemoto, M.; Bannai, H.; Tsujimura, K.; Kobayashi, M.; Kikuchi, T.; Yamanaka, T.; Kondo, T. Getah Virus Infection among Racehorses, Japan, 2014. Emerg. Infect. Dis. 2015, 21, 883–885. [Google Scholar] [CrossRef] [PubMed]
  22. Miao, Q.; Nguyen, W.; Zhu, J.; Liu, G.; van Oers, M.M.; Tang, B.; Yan, K.; Larcher, T.; Suhrbier, A.; Pijlman, G.P. A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice. Vaccine 2024, 42, 126136. [Google Scholar] [CrossRef] [PubMed]
  23. Rawle, D.J.; Hugo, L.E.; Cox, A.L.; Devine, G.J.; Suhrbier, A. Generating prophylactic immunity against arboviruses in vertebrates and invertebrates. Nat. Rev. Immunol. 2024, 24, 621–636. [Google Scholar] [CrossRef] [PubMed]
  24. Pan, J.; Zhang, H.; Chen, X.; Zeng, M.; Han, H.; Guo, Y.; Li, J.; Luo, S.; Yan, G.; Chen, S. Evolutionary characterization and pathogenicity of Getah virus from pigs in Guangdong Province of China. Arch. Virol. 2023, 168, 258. [Google Scholar] [CrossRef] [PubMed]
  25. Yuan, X.; Yu, B.; Ma, X.; Xu, L.; Su, F.; Sun, H.; Shao, K.; Xiong, T.; Li, J.; Ye, S. Isolation and Molecular Characterization of Emerging Getah Virus Genotype III Variant Strains from Swine in Southeastern China (2024–2025). Int. J. Mol. Sci. 2026, 27, 6016. [Google Scholar] [CrossRef] [PubMed]
  26. Sun, Y.; Yang, H.; Zhang, Y.; Liu, R.; Li, L.; Shi, M.; Liu, T.; Du, J.; Guo, Z.; Zhao, L. Outbreak and epidemic of Getah virus infection in swine by virulence-enhanced GIII variant in Henan, central China in 2024. Virulence 2025, 16, 2530661. [Google Scholar] [CrossRef] [PubMed]
  27. Yang, Z.; Yan, W.; Wang, X.; Zhang, M.; Peng, Z.; Zhang, M.; Ghonaim, A.H.; Yu, X.; Vy, T.T.; Ku, X.; et al. Isolation and Characterization of a Highly Virulent Getah Virus Causing Acute Lethal Infection in Neonatal Piglets. Transbound. Emerg. Dis. 2026, 2026, 2271732. [Google Scholar] [CrossRef] [PubMed]
  28. Jia, H.; Kang, H.; Chu, P.; Wang, T.; Guo, Y.; Chen, J.; Li, J.; Zhou, X.; Ran, D.-L.; Du, L.-Y.; et al. Re-Emergence and Characterization of a Highly Pathogenic Getah Virus on a Pig Farm in Guangdong Province, China. Microorganisms 2026, 14, 846. [Google Scholar] [CrossRef] [PubMed]
  29. Chu, P.P.; Guo, H.; Zhou, X.; Chen, S.N.; Sun, X.; Tian, S.; Zou, Y.G.; Li, C.L.; Zhang, R.; Zhai, S.L. Emergence of a novel GIII Getah virus variant in pigs in Guangdong, China, 2023. Microbiol. Spectr. 2024, 12, e0048324. [Google Scholar] [CrossRef] [PubMed]
  30. Wu, Y.; Gao, X.; Kuang, Z.; Lin, L.; Zhang, H.; Yin, L.; Hong, J.; Ren, B.; Li, Q.; Wang, L. Isolation and pathogenicity of a highly virulent group III porcine Getah virus in China. Front. Cell Infect. Microbiol. 2024, 14, 1494654. [Google Scholar] [CrossRef] [PubMed]
  31. Kumanomido, T.; Wada, R.; Kanemaru, T.; Kamada, M.; Akiyama, Y.; Matumoto, M. Transplacental infection in mice inoculated with Getah virus. Vet. Microbiol. 1988, 16, 129–136. [Google Scholar] [CrossRef] [PubMed]
  32. Taylor, A.; Herrero, L.J.; Rudd, P.A.; Mahalingam, S. Mouse models of alphavirus-induced inflammatory disease. J. General. Virol. 2015, 96, 221–238. [Google Scholar] [CrossRef] [PubMed]
  33. Wang, A.; Zhou, F.; Liu, C.; Gao, D.; Qi, R.; Yin, Y.; Liu, S.; Gao, Y.; Fu, L.; Xia, Y.; et al. Structure of infective Getah virus at 2.8 A resolution determined by cryo-electron microscopy. Cell Discov. 2022, 8, 12. [Google Scholar] [CrossRef] [PubMed]
  34. Danis, B.; George, T.C.; Goriely, S.; Dutta, B.; Renneson, J.; Gatto, L.; Fitzgerald-Bocarsly, P.; Marchant, A.; Goldman, M.; Willems, F.; et al. Interferon regulatory factor 7-mediated responses are defective in cord blood plasmacytoid dendritic cells. Eur. J. Immunol. 2008, 38, 507–517. [Google Scholar] [CrossRef] [PubMed]
  35. Lau-Kilby, A.W.; Turfkruyer, M.; Kehl, M.; Yang, L.; Buchholz, U.J.; Hickey, K.; Malloy, A.M.W. Type I IFN ineffectively activates neonatal dendritic cells limiting respiratory antiviral T-cell responses. Mucosal Immunol. 2020, 13, 371–380. [Google Scholar] [CrossRef] [PubMed]
  36. De Wit, D.; Olislagers, V.; Goriely, S.; Vermeulen, F.; Wagner, H.; Goldman, M.; Willems, F. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 2004, 103, 1030–1032. [Google Scholar] [CrossRef] [PubMed]
  37. Cormier, S.A.; Shrestha, B.; Saravia, J.; Lee, G.I.; Shen, L.; DeVincenzo, J.P.; Kim, Y.-i.; You, D. Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection. J. Virol. 2014, 88, 9350–9360. [Google Scholar] [CrossRef] [PubMed]
  38. Carpentier, K.S.; Morrison, T.E. Innate immune control of alphavirus infection. Curr. Opin. Virol. 2018, 28, 53–60. [Google Scholar] [CrossRef] [PubMed]
  39. Ryman, K.D.; Klimstra, W.B.; Nguyen, K.B.; Biron, C.A.; Johnston, R.E. Alpha/Beta Interferon Protects Adult Mice from Fatal Sindbis Virus Infection and Is an Important Determinant of Cell and Tissue Tropism. J. Virol. 2000, 74, 3366–3378. [Google Scholar] [CrossRef] [PubMed]
  40. Rudd, P.A.; Wilson, J.; Gardner, J.; Larcher, T.; Babarit, C.; Le, T.T.; Anraku, I.; Kumagai, Y.; Loo, Y.M.; Gale, M., Jr.; et al. Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock. J. Virol. 2012, 86, 9888–9898. [Google Scholar] [CrossRef] [PubMed]
  41. Prow, N.A.; Tang, B.; Gardner, J.; Le, T.T.; Taylor, A.; Poo, Y.S.; Nakayama, E.; Hirata, T.D.C.; Nakaya, H.I.; Slonchak, A.; et al. Lower temperatures reduce type I interferon activity and promote alphaviral arthritis. PLoS Pathog. 2017, 13, e1006788. [Google Scholar] [CrossRef] [PubMed]
  42. Marín-Lopez, A.; Calvo-Pinilla, E.; Moreno, S.; Utrilla-Trigo, S.; Nogales, A.; Brun, A.; Fikrig, E.; Ortego, J. Modeling Arboviral Infection in Mice Lacking the Interferon Alpha/Beta Receptor. Viruses 2019, 11, 35. [Google Scholar] [CrossRef] [PubMed]
  43. da Silva, J.S.d.F.; Ferreira Junior, C.V.; Dos Santos, L.M.S.; Andrade-Neto, V.F.d.; Guedes, P.M.d.M.; Yaochite, J.N.U.; França, R.F.D.O.; Brito, R.M.d.M.; Nascimento, M.S.L. Innate immune sensing of alphavirus chikungunya: Balancing antiviral defense and pathogenesis. Front. Immunol. 2026, 17, 1810208. [Google Scholar] [CrossRef] [PubMed]
  44. Chen, J.; Wu, H.; Lin, A.; Miu, X.; Li, Y.; Zhu, Q.; Lu, Y.; Zhang, X.; Zhang, Z.; Li, K. Attenuation Profile and Molecular Characterization of a High-Passaged Attenuated Getah Virus Strain. Transbound. Emerg. Dis. 2025, 2025, 2787909. [Google Scholar] [CrossRef] [PubMed]
  45. Jiang, Z.; Merits, A.; Qin, Y.; Xing, G.; Zhang, L.; Chen, J.; Wang, N.; Varjak, M.; Zhai, X.; Li, D.; et al. Attenuated Getah virus confers protection against multiple arthritogenic alphaviruses. PLoS Pathog. 2024, 20, e1012700. [Google Scholar] [CrossRef] [PubMed]
  46. Liu, B.; Wang, Y.; Shao, L.; Chen, Y.; Xu, Z.; Zhu, L. Antiviral activity of Scutellaria baicalensis Georgi Extract against Getah virus in vivo and in vitro. Front. Vet. Sci. 2025, 12, 1551501. [Google Scholar] [CrossRef] [PubMed]
  47. Ren, T.; Zhou, L.; Min, X.; Sui, M.; Zhi, X.; Mo, Y.; Huang, J.; Zhang, K.; Liu, W.; Wang, H.; et al. Development of a recombinant reporter Getah virus for antiviral drug screening assays. Vet. Microbiol. 2023, 281, 109742. [Google Scholar] [CrossRef] [PubMed]
  48. Wei, B.; Xing, L.; Sun, S.; Zhang, P.; Dong, Y.; Yang, H. Establishment of reverse transcription recombinase-aided amplification with lateral flow dipstick for the rapid visual detection of Getah virus. Front. Cell. Infect. Microbiol. 2025, 15, 1631048. [Google Scholar] [CrossRef] [PubMed]
  49. Liu, Z.; Yang, F.; Fang, M.; Wu, Q.; Fan, K.; Huang, D.; Ye, Y.; Wan, G.; Song, D. Rapid and Sensitive One-Tube Detection of Getah Virus Using RT-LAMP Combined with Pyrococcus furiosus Argonaute. Vet. Sci. 2025, 12, 93. [Google Scholar] [CrossRef] [PubMed]
  50. Ivashkiv, L.B.; Donlin, L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014, 14, 36–49. [Google Scholar] [CrossRef] [PubMed]
  51. Wilson, J.A.; Prow, N.A.; Schroder, W.A.; Ellis, J.J.; Cumming, H.E.; Gearing, L.J.; Poo, Y.S.; Taylor, A.; Hertzog, P.J.; Di Giallonardo, F.; et al. RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation. PLoS Pathog. 2017, 13, e1006155. [Google Scholar] [CrossRef] [PubMed]
  52. Hick, T.A.H.; Geertsema, C.; Nguyen, W.; Bishop, C.R.; van Oosten, L.; Abbo, S.R.; Dumenil, T.; van Kuppeveld, F.J.M.; Langereis, M.A.; Rawle, D.J.; et al. Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo. Mol. Ther. 2024, 32, 2519–2534. [Google Scholar] [CrossRef] [PubMed]
  53. Zhao, B.; Du, B.; Wang, J.; Zhang, Z.; Yang, D.; He, X.; Wang, J. Establishment of a mouse model for studying emerging Getah virus pathogenesis and vaccine efficacy. J. Integr. Agric. 2026, in press. [Google Scholar] [CrossRef]
  54. Couderc, T.; Chrétien, F.; Schilte, C.; Disson, O.; Brigitte, M.; Guivel-Benhassine, F.; Touret, Y.; Barau, G.; Cayet, N.; Schuffenecker, I. A mouse model for Chikungunya: Young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 2008, 4, e29. [Google Scholar] [CrossRef] [PubMed]
  55. Kurosu, T.; Okuzaki, D.; Sakai, Y.; Kadi, M.A.; Phanthanawiboon, S.; Ami, Y.; Shimojima, M.; Yoshikawa, T.; Fukushi, S.; Nagata, N. Dengue virus infection induces selective expansion of Vγ4 and Vγ6TCR γδ T cells in the small intestine and a cytokine storm driving vascular leakage in mice. PLoS Neglected Trop. Dis. 2023, 17, e0011743. [Google Scholar] [CrossRef] [PubMed]
  56. Liu, J.; Jing, W.; Fang, Y.; He, X.; Chen, G.; Jia, H.; Wang, J.; Jing, Z. The Infection of the Japanese Encephalitis Virus SA14-14-2 Strain Induces Lethal Peripheral Inflammatory Responses in IFNAR Deficiency Mice. Front. Microbiol. 2022, 12, 823825. [Google Scholar] [CrossRef] [PubMed]
  57. Rawle, D.J.; Le, T.T.; Dumenil, T.; Bishop, C.; Yan, K.; Nakayama, E.; Bird, P.I.; Suhrbier, A. Widespread discrepancy in Nnt genotypes and genetic backgrounds complicates granzyme A and other knockout mouse studies. eLife 2022, 11, e70207. [Google Scholar] [CrossRef] [PubMed]
  58. Nakayama, E.; Tang, B.; Stewart, R.; Cox, A.L.; Yan, K.; Bishop, C.R.; Dumenil, T.; Nguyen, W.; Slonchak, A.; Sng, J.; et al. Evolution of Zika virus in Rag1-deficient mice selects for unique envelope glycosylation motif mutants that show enhanced replication fitness. Virus Evol. 2025, 11, veaf021. [Google Scholar] [CrossRef] [PubMed]
  59. Dumenil, T.; Le, T.T.; Rawle, D.J.; Yan, K.; Tang, B.; Nguyen, W.; Bishop, C.; Suhrbier, A. Warmer ambient air temperatures reduce nasal turbinate and brain infection, but increase lung inflammation in the K18-hACE2 mouse model of COVID-19. Sci. Total Environ. 2023, 859, 160163. [Google Scholar] [CrossRef] [PubMed]
  60. Poo, Y.S.; Rudd, P.A.; Gardner, J.; Wilson, J.A.; Larcher, T.; Colle, M.A.; Le, T.T.; Nakaya, H.I.; Warrilow, D.; Allcock, R.; et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl. Trop. Dis. 2014, 8, e3354. [Google Scholar] [CrossRef] [PubMed]
  61. Bankhead, P.; Loughrey, M.B.; Fernández, J.A.; Dombrowski, Y.; McArt, D.G.; Dunne, P.D.; McQuaid, S.; Gray, R.T.; Murray, L.J.; Coleman, H.G. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 2017, 7, 16878. [Google Scholar] [CrossRef] [PubMed]
  62. Bishop, C.R.; Yan, K.; Nguyen, W.; Rawle, D.J.; Tang, B.; Larcher, T.; Suhrbier, A. Microplastics dysregulate innate immunity in the SARS-CoV-2 infected lung. Front. Immunol. 2024, 15, 1382655. [Google Scholar] [CrossRef] [PubMed]
  63. Carolin, A.; Yan, K.; Bishop, C.R.; Tang, B.; Nguyen, W.; Rawle, D.J.; Suhrbier, A. Tracking inflammation resolution signatures in lungs after SARS-CoV-2 omicron BA.1 infection of K18-hACE2 mice. PLoS ONE 2024, 19, e0302344. [Google Scholar] [CrossRef] [PubMed]
  64. Carolin, A.; Frazer, D.; Yan, K.; Bishop, C.R.; Tang, B.; Nguyen, W.; Helman, S.L.; Horvat, J.; Larcher, T.; Rawle, D.J.; et al. The effects of iron deficient and high iron diets on SARS-CoV-2 lung infection and disease. Front. Microbiol. 2024, 15, 1441495. [Google Scholar] [CrossRef] [PubMed]
  65. IPA Training: Maximizing the Biological Interpretation of Gene, Transcript & Protein Expression Data with IPA. Available online: https://chhe.research.ncsu.edu/wordpress/wp-content/uploads/2015/10/IPA-Data-Analysis-training-slides-2016_04.pdf.
  66. Pinto, A.K.; Brien, J.D.; Lam, C.Y.; Johnson, S.; Chiang, C.; Hiscott, J.; Sarathy, V.V.; Barrett, A.D.; Shresta, S.; Diamond, M.S. Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. mBio 2015, 6, e01316-01315. [Google Scholar] [CrossRef] [PubMed]
  67. Nurhalimah, C. The Comprehensive Systematic Review of Platelet Count and Hematocrit as Predictors of Plasma Leakage in Dengue Hemorrhagic Fever. Int. J. Med. Sci. Health Res. 2026, 35, 97–133. [Google Scholar] [CrossRef]
  68. Mahapatra, S.; Heffner, A.; Atarthi-Dugan, J. Septic Shock. In StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, 2023. Available online: https://www.ncbi.nlm.nih.gov/books/NBK430939/.
  69. Nwe, K.M.; Ngwe Tun, M.M.; Myat, T.W.; Sheng Ng, C.F.; Htun, M.M.; Lin, H.; Hom, N.S.; Soe, A.M.; Elong Ngono, A.; Hamano, S.; et al. Acute-phase Serum Cytokine Levels and Correlation with Clinical Outcomes in Children and Adults with Primary and Secondary Dengue Virus Infection in Myanmar between 2017 and 2019. Pathogens 2022, 11, 558. [Google Scholar] [CrossRef] [PubMed]
  70. Shresta, S.; Sharar, K.L.; Prigozhin, D.M.; Beatty, P.R.; Harris, E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 2006, 80, 10208–10217. [Google Scholar] [CrossRef] [PubMed]
  71. Green, S.; Vaughn, D.W.; Kalayanarooj, S.; Nimmannitya, S.; Suntayakorn, S.; Nisalak, A.; Lew, R.; Innis, B.L.; Kurane, I.; Rothman, A.L.; et al. Early Immune Activation in Acute Dengue Illness Is Related to Development of Plasma Leakage and Disease Severity. J. Infect. Dis. 1999, 179, 755–762. [Google Scholar] [CrossRef] [PubMed]
  72. Yu, H.; Yang, Q.; Qian, Y.; Luo, S.; Kong, T.; Yang, G.; Chen, W.; Xie, F.; Chen, J.; Xiong, X. A positive correlation between serum lactate dehydrogenase level and in-hospital mortality in ICU sepsis patients: Evidence from two large databases. Eur. J. Med. Res. 2024, 29, 525. [Google Scholar] [CrossRef] [PubMed]
  73. Azar, S.R.; Campos, R.K.; Bergren, N.A.; Camargos, V.N.; Rossi, S.L. Epidemic Alphaviruses: Ecology, Emergence and Outbreaks. Microorganisms 2020, 8, 1167. [Google Scholar] [CrossRef] [PubMed]
  74. Barr, K.L.; Vaidhyanathan, V. Chikungunya in Infants and Children: Is Pathogenesis Increasing? Viruses 2019, 11, 294. [Google Scholar] [CrossRef] [PubMed]
  75. Waechter, R.; Ingraham, E.; Evans, R.; Cudjoe, N.; Krystosik, A.; Isaac, R.; Watts, A.; Noel, T.; Landon, B.; Fernandes, M.; et al. Pre and postnatal exposure to Chikungunya virus does not affect child neurodevelopmental outcomes at two years of age. PLoS Negl. Trop. Dis. 2020, 14, e0008546. [Google Scholar] [CrossRef] [PubMed]
  76. Ferraz, A.C.; Almeida, L.T.; da Silva Caetano, C.C.; da Silva Menegatto, M.B.; Lima, R.L.S.; de Senna, J.P.N.; de Oliveira Cardoso, J.M.; Perucci, L.O.; Talvani, A.; de Lima, W.G. Hepatoprotective, antioxidant, anti-inflammatory, and antiviral activities of silymarin against mayaro virus infection. Antivir. Res. 2021, 194, 105168. [Google Scholar] [CrossRef] [PubMed]
  77. Arshad, K.; Sheikh, S.; Naqvi, S.U.-u.-B.; Sarwar, I.; Javaid, S.; Asghar, M.; Butt, M.A. Frequency of splenomegaly in dengue fever in children. J. Ayub Med. Coll. Abbottabad 2015, 27, 356–359. [Google Scholar] [PubMed]
  78. Gardner, J.; Anraku, I.; Le, T.T.; Larcher, T.; Major, L.; Roques, P.; Schroder, W.A.; Higgs, S.; Suhrbier, A. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 2010, 84, 8021–8032. [Google Scholar] [CrossRef] [PubMed]
  79. Bishop, C.R.; Caten, F.T.; Nakaya, H.I.; Suhrbier, A. Chikungunya patient transcriptional signatures faithfully recapitulated in a C57BL/6J mouse model. Front. Immunol. 2022, 13, 1092370. [Google Scholar] [CrossRef] [PubMed]
  80. Bishop, C.R.; Dumenil, T.; Rawle, D.J.; Le, T.T.; Yan, K.; Tang, B.; Hartel, G.; Suhrbier, A. Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression. PLoS Pathog. 2022, 18, e1010867. [Google Scholar] [CrossRef] [PubMed]
  81. Baxter, V.K.; Heise, M.T. Immunopathogenesis of alphaviruses. Adv. Virus Res. 2020, 107, 315–382. [Google Scholar] [CrossRef] [PubMed]
  82. Schuermans, S.; Kestens, C.; Marques, P.E. Systemic mechanisms of necrotic cell debris clearance. Cell Death Dis. 2024, 15, 557. [Google Scholar] [CrossRef] [PubMed]
  83. Hazlewood, J.E.; Dumenil, T.; Le, T.T.; Slonchak, A.; Kazakoff, S.H.; Patch, A.-M.; Gray, L.-A.; Howley, P.M.; Liu, L.; Hayball, J.D.; et al. Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures. PLoS Pathog. 2021, 17, e1009215. [Google Scholar] [CrossRef] [PubMed]
  84. Xie, F.; Zhu, Q. The regulation of cGAS-STING signaling by RNA virus-derived components. Virol. J. 2024, 21, 101. [Google Scholar] [CrossRef] [PubMed]
  85. Beisel, C.; Ziegler, S.; Martrus Zapater, G.; Chapel, A.; Griesbeck, M.; Hildebrandt, H.; Lohse, A.W.; Altfeld, M. TLR7-mediated activation of XBP1 correlates with the IFNα production in humans. Cytokine 2017, 94, 55–58. [Google Scholar] [CrossRef] [PubMed]
  86. Nguyen, B.H.; Stanley, E.; Baxter, V.K.; Griffin, D.E. Interferon-β Modulates Early Viral Replication Kinetics and Innate Responses to Non-Fatal Alphavirus Encephalomyelitis. Pathogens 2026, 15, 441. [Google Scholar] [CrossRef] [PubMed]
  87. Feyzi, K.; Mousavi, F.S.; Abbasi, S. Pathogen-Specific Evasion of Innate Immunity by Alphaviruses (CHIKV, VEEV, and SINV). Rev. Med. Virol. 2026, 36, e70174. [Google Scholar] [CrossRef] [PubMed]
  88. Gürtler, L.; Schramm, W.; Seitz, R. Viral sepsis–pathophysiology and disease manifestation. Infection 2025, 53, 775–784. [Google Scholar] [CrossRef] [PubMed]
  89. Sharma, A.; Kontodimas, K.; Bosmann, M. The MAVS immune recognition pathway in viral infection and sepsis. Antioxid. Redox Signal. 2021, 35, 1376–1392. [Google Scholar] [CrossRef] [PubMed]
  90. Marques, A.; Torre, C.; Pinto, R.; Sepodes, B.; Rocha, J. Treatment advances in sepsis and septic shock: Modulating pro-and anti-inflammatory mechanisms. J. Clin. Med. 2023, 12, 2892. [Google Scholar] [CrossRef] [PubMed]
  91. Vella, R.; Panci, D.; Carini, F.; Malta, G.; Vieni, S.; David, S.; Albano, G.D.; Puntarello, M.; Zerbo, S.; Argo, A. Cytokines in sepsis: A critical review of the literature on systemic inflammation and multiple organ dysfunction. Front. Immunol. 2025, 16, 1682306. [Google Scholar] [CrossRef] [PubMed]
  92. Schulte, W.; Bernhagen, J.; Bucala, R. Cytokines in sepsis: Potent immunoregulators and potential therapeutic targets—An updated view. Mediat. Inflamm. 2013, 2013, 165974. [Google Scholar] [CrossRef] [PubMed]
  93. Zanotti, S.; Kumar, A.; Kumar, A. Cytokine modulation in sepsis and septic shock. Expert Opin. Investig. Drugs 2002, 11, 1061–1075. [Google Scholar] [CrossRef] [PubMed]
  94. Chang, D.; Dela Cruz, C.; Sharma, L. Beneficial and Detrimental Effects of Cytokines during Influenza and COVID-19. Viruses 2024, 16, 308. [Google Scholar] [CrossRef] [PubMed]
  95. Thomas-Rüddel, D.; Giamarellos-Bourboulis, E.; Neumann, C.; Briegel, J.; Roquilly, A.; Annane, D.; Wetzker, R.; Bauer, M. IFNγ in human sepsis: A scoping review. Ann. Intensive Care 2025, 15, 112. [Google Scholar] [CrossRef] [PubMed]
  96. Martín-Fernández, M.; Tamayo-Velasco, Á.; Aller, R.; Gonzalo-Benito, H.; Martínez-Paz, P.; Tamayo, E. Endothelial Dysfunction and Neutrophil Degranulation as Central Events in Sepsis Physiopathology. Int. J. Mol. Sci. 2021, 22, 6272. [Google Scholar] [CrossRef] [PubMed]
  97. Rolle, A.; Schepers, K.; Cassadou, S.; Curlier, E.; Madeux, B.; Hermann-Storck, C.; Fabre, I.; Lamaury, I.; Tressieres, B.; Thiery, G. Severe sepsis and septic shock associated with chikungunya virus infection, Guadeloupe, 2014. Emerg. Infect. Dis. 2016, 22, 891. [Google Scholar] [CrossRef] [PubMed]
  98. Karki, R.; Sharma, B.R.; Tuladhar, S. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 2021, 184, 149–168.e117. [Google Scholar] [CrossRef] [PubMed]
  99. Takahama, M.; Patil, A.; Richey, G. A pairwise cytokine code explains the organism-wide response to sepsis. Nat. Immunol. 2024, 25, 226–239. [Google Scholar] [CrossRef] [PubMed]
  100. Giamarellos-Bourboulis, E.J.; Antonelli, M.; Bloos, F.; Kotsamidi, I.; Psarrakis, C.; Dakou, K.; Thomas-Rüddel, D.; Montini, L.; Briegel, J.; Damoraki, G. Interferon-gamma driven elevation of CXCL9: A new sepsis endotype independently associated with mortality. eBioMedicine 2024, 109, 105414. [Google Scholar] [CrossRef] [PubMed]
  101. de Farias, E.C.F.; Carvalho, P.B.; do Nascimento, L.M.P.P.; Pinheiro, A.H.O.; Alves, M.C.B.; Machado-Ferraro, K.M.M.; Aires, L.F.Q.; Dias, L.G.; Machado, M.M.M.; Serrão, M.J.D.; et al. IL-6, IFN-γ, IL-17A elevations and glutathione depletion predict severe MODS and mortality in critically ill children with COVID-19 and bacterial sepsis: A prospective cohort study from the Brazilian Amazon. Cytokine 2025, 196, 157043. [Google Scholar] [CrossRef] [PubMed]
  102. Kawa, K.; Tsutsui, H.; Uchiyama, R.; Kato, J.; Matsui, K.; Iwakura, Y.; Matsumoto, T.; Nakanishi, K. IFN-γ is a master regulator of endotoxin shock syndrome in mice primed with heat-killed Propionibacterium acnes. Int. Immunol. 2010, 22, 157–166. [Google Scholar] [CrossRef] [PubMed]
  103. Chakravarti, A.; Kumaria, R. Circulating levels of tumour necrosis factor-alpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. Indian J. Med. Res. 2006, 123, 25–30. [Google Scholar] [PubMed]
  104. Tilahun, A.Y.; Holz, M.; Wu, T.-T.; David, C.S.; Rajagopalan, G. Interferon Gamma-Dependent Intestinal Pathology Contributes to the Lethality in Bacterial Superantigen-Induced Toxic Shock Syndrome. PLoS ONE 2011, 6, e16764. [Google Scholar] [CrossRef] [PubMed]
  105. Li, H.; Liu, L.; Zhang, D.; Xu, J.; Dai, H.; Tang, N.; Su, X.; Cao, B. SARS-CoV-2 and viral sepsis: Observations and hypotheses. Lancet 2020, 395, 1517–1520. [Google Scholar] [CrossRef] [PubMed]
  106. Tuyen, T.T.; Viet, N.T.; Hang, N.T.; Giang, N.T.; Anh, D.D.; Anh, D.T.; Hung, H.V.; Quyet, D.; Toan, N.L.; Cam, T.D.; et al. Proinflammatory Cytokines Are Modulated in Vietnamese Patients with Dengue Fever. Viral Immunol. 2020, 33, 514–520. [Google Scholar] [CrossRef] [PubMed]
  107. Pan, P.; Zhang, Q.; Liu, W. Dengue virus infection activates interleukin-1β to induce tissue injury and vascular leakage. Front. Microbiol. 2019, 10, 2637. [Google Scholar] [CrossRef] [PubMed]
  108. Cannon, J.G.; Tompkins, R.G.; Gelfand, J.A.; Michie, H.R.; Stanford, G.G.; van der Meer, J.W.M.; Endres, S.; Lonnemann, G.; Corsetti, J.; Chernow, B.; et al. Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever. J. Infect. Dis. 1990, 161, 79–84. [Google Scholar] [CrossRef] [PubMed]
  109. Pachot, A.; Monneret, G.; Voirin, N.; Leissner, P.; Venet, F.; Bohé, J.; Payen, D.; Bienvenu, J.; Mougin, B.; Lepape, A. Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock. Clin. Immunol. 2005, 114, 61–69. [Google Scholar] [CrossRef] [PubMed]
  110. Hottz, E.D.; Lopes, J.F.; Freitas, C.; Valls-de-Souza, R.; Oliveira, M.F.; Bozza, M.T.; Da Poian, A.T.; Weyrich, A.S.; Zimmerman, G.A.; Bozza, F.A.; et al. Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. Blood 2013, 122, 3405–3414. [Google Scholar] [CrossRef] [PubMed]
  111. Li, Z.; Hu, J.; Bao, C.; Gao, C.; Zhang, N.; Cardona, C.J.; Xing, Z. Activation of the NLRP3 inflammasome and elevation of interleukin-1β secretion in infection by sever fever with thrombocytopenia syndrome virus. Sci. Rep. 2022, 12, 2573. [Google Scholar] [CrossRef] [PubMed]
  112. Griffiths, M.J.; Ooi, M.H.; Wong, S.C.; Mohan, A.; Podin, Y.; Perera, D.; Chieng, C.H.; Tio, P.H.; Cardosa, M.J.; Solomon, T. In Enterovirus 71 Encephalitis With Cardio-Respiratory Compromise, Elevated Interleukin 1β, Interleukin 1 Receptor Antagonist, and Granulocyte Colony-Stimulating Factor Levels Are Markers of Poor Prognosis. J. Infect. Dis. 2012, 206, 881–892. [Google Scholar] [CrossRef] [PubMed]
  113. Jia, F.; Wang, G.; Xu, J.; Long, J.; Deng, F.; Jiang, W. Role of tumor necrosis factor-α in the mortality of hospitalized patients with severe and critical COVID-19 pneumonia. Aging 2021, 13, 23895. [Google Scholar] [CrossRef] [PubMed]
  114. Marks, J.D.; Marks, C.B.; Ljuce, J.M.; Montgomery, A.B.; Turner, J.; Metz, C.A.; Murray, J.F. Plasma tumor necrosis factor in patients with septic shock: Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am. Rev. Respir. Dis. 1990, 141, 94–97. [Google Scholar] [CrossRef] [PubMed]
  115. O’Dwyer, M.J.; Mankan, A.K.; Stordeur, P.; O’Connell, B.; Duggan, E.; White, M.; Kelleher, D.P.; McManus, R.; Ryan, T. The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock 2006, 26, 5–6. [Google Scholar] [CrossRef]
  116. Endo, S.; Inada, K.; Inoue, Y.; Kuwata, Y.; Suzuki, M.; Yamashita, H.; Hoshi, S.; Yoshida, M. Two types of septic shock classified by the plasma levels of cytokines and endotoxin. Circ. Shock 1992, 38, 264–274. [Google Scholar] [PubMed]
  117. Tamayo-Velasco, A.; Martinez-Paz, P.; Penarrubia-Ponce, M.J.; De la Fuente, I.; Perez-Gonzalez, S.; Fernandez, I.; Duenas, C.; Gomez-Sanchez, E.; Lorenzo-Lopez, M.; Gomez-Pesquera, E. HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients. J. Clin. Med. 2021, 10, 2017. [Google Scholar] [CrossRef] [PubMed]
  118. Benjamin, J.T.; Moore, D.J.; Bennett, C.; van der Meer, R.; Royce, A.; Loveland, R.; Wynn, J.L. Cutting Edge: IL-1α and Not IL-1β Drives IL-1R1–Dependent Neonatal Murine Sepsis Lethality. J. Immunol. 2018, 201, 2873–2878. [Google Scholar] [CrossRef] [PubMed]
  119. Mehta, P.; Porter, J.C.; Manson, J.J.; Isaacs, J.D.; Openshaw, P.J.M.; McInnes, I.B.; Summers, C.; Chambers, R.C. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: Challenges and opportunities. Lancet Respir. Med. 2020, 8, 822–830. [Google Scholar] [CrossRef] [PubMed]
  120. Huang, H.; Wang, S.; Jiang, T.; Fan, R.; Zhang, Z.; Mu, J.; Li, K.; Wang, Y.; Jin, L.; Lin, F. High levels of circulating GM-CSF+ CD4+ T cells are predictive of poor outcomes in sepsis patients: A prospective cohort study. Cell. Mol. Immunol. 2019, 16, 602–610. [Google Scholar] [CrossRef] [PubMed]
  121. Thwaites, R.S.; Sanchez Sevilla Uruchurtu, A.; Siggins, M.K.; Liew, F.; Russell, C.D.; Moore, S.C.; Fairfield, C.; Carter, E.; Abrams, S.; Short, C.-E.; et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci. Immunol. 2021, 6, eabg9873. [Google Scholar] [CrossRef] [PubMed]
  122. Lee, S.J.; Kim, J.; Han, M.; Lee, J.A.; Lee, Y.; Kim, J.H.; Ahn, J.Y.; Jeong, S.J.; Ku, N.S.; Yeom, J.-S. Distinct plasma cytokine and chemokine profiles in severe COVID-19 and septic shock. PLoS ONE 2026, 21, e0347126. [Google Scholar] [CrossRef] [PubMed]
  123. Torre, D.; Tambini, R.; Manfredi, M.; Mangani, V.; Livi, P.; Maldifassi, V.; Chiaranda, M.; Campi, P.; Speranza, F. Circulating levels of granulocyte macrophage colony-stimulating factor in patients with the systemic inflammatory response syndrome. J. Infect. 2003, 47, 296–299. [Google Scholar] [CrossRef] [PubMed]
  124. Basu, S.; Dunn, A.R.; Marino, M.W.; Savoia, H.; Hodgson, G.; Lieschke, G.J.; Cebon, J. Increased tolerance to endotoxin by granulocyte-macrophage colony-stimulating factor-deficient mice. J. Immunol. 1997, 159, 1412–1417. [Google Scholar] [CrossRef]
  125. Gowri Sankar, S.; Alwin Prem Anand, A. Cytokine IP-10 and GM-CSF are prognostic biomarkers for severity in secondary dengue infection. Hum. Immunol. 2021, 82, 438–445. [Google Scholar] [CrossRef] [PubMed]
  126. Linch, S.N.; Kelly, A.M.; Danielson, E.T.; Pero, R.; Lee, J.J.; Gold, J.A. Interleukin 5 is protective during sepsis in an eosinophil-independent manner. Am. J. Respir. Crit. Care Med. 2012, 186, 246–254. [Google Scholar] [CrossRef] [PubMed]
  127. Taha, S.I.; El Sehsah, E.M.; Fouad, S.H.; Ezzelregal, H.G.; Moussa, A.H.; Abdalgeleel, S.A.; Abdelmaksoud, M.F. Interleukin-5, Interleukin-6 and Eosinophils in COVID-19 Egyptian Patients: Potential Clues for Prognosis and Immunotherapy. Int. J. Med. Arts 2022, 4, 1993–2000. [Google Scholar] [CrossRef]
  128. Karhu, J.; Ala-Kokko, T.I.; Vuorinen, T.; Ohtonen, P.; Julkunen, I.; Syrjälä, H.T. Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients. Cytokine 2019, 113, 272–276. [Google Scholar] [CrossRef] [PubMed]
  129. Gong, Y.; Yan, X.; Sun, X.; Chen, T.; Liu, Y.; Cao, J. Oncostatin M is a prognostic biomarker and inflammatory mediator for sepsis. J. Infect. Dis. 2020, 221, 1989–1998. [Google Scholar] [CrossRef] [PubMed]
  130. Ricaño-Ponce, I.; Riza, A.-L.; de Nooijer, A.H.; Pirvu, A.; Dorobantu, S.; Dragos, A.; Streata, I.; Roskanovic, M.; Grondman, I.; Dumitrescu, F.; et al. Characterization of sepsis inflammatory endotypes using circulatory proteins in patients with severe infection: A prospective cohort study. BMC Infect. Dis. 2022, 22, 778. [Google Scholar] [CrossRef] [PubMed]
  131. López-Cortés, A.; Guerrero, S.; Ortiz-Prado, E.; Yumiceba, V.; Vera-Guapi, A.; León Cáceres, Á.; Simbaña-Rivera, K.; Gómez-Jaramillo, A.M.; Echeverría-Garcés, G.; García-Cárdenas, J.M. Pulmonary inflammatory response in lethal COVID-19 reveals potential therapeutic targets and drugs in phases III/IV clinical trials. Front. Pharmacol. 2022, 13, 833174. [Google Scholar] [CrossRef] [PubMed]
  132. Van Nynatten, L.R.; Tweddell, D.; Daley, M.; Cepinskas, G.; Basmaji, J.; Slessarev, M.; Fraser, D.D. Pathway-level profiling of the sepsis proteome reveals immune and transcriptional dysregulation. Mol. Med. 2026, 32, 74. [Google Scholar] [CrossRef] [PubMed]
  133. Froeschle, G.M.; Bedke, T.; Boettcher, M.; Huber, S.; Singer, D.; Ebenebe, C.U. T cell cytokines in the diagnostic of early-onset sepsis. Pediatr. Res. 2021, 90, 191–196. [Google Scholar] [CrossRef] [PubMed]
  134. Vivanco-Cid, H.; Maldonado-Renteria, M.; Sanchez-Vargas, L.; Izaguirre-Hernandez, I.; Hernandez-Flores, K.; Remes-Ruiz, R. Dynamics of interleukin-21 production during the clinical course of primary and secondary dengue virus infections. Immunol. Lett. 2014, 161, 89–95. [Google Scholar] [CrossRef] [PubMed]
  135. Öztürk, N.A.A.; Ursavaş, A.; Dilektaşlı, A.G.; Demirdöğen, E.; Coşkun, F.; Ediger, D.; Uzaslan, E.; Yöyen-Ermiş, D.; Karaca, M.; Terzi, O. IL-21: A Potential Biomarker For Diagnosis and Predicting Prognosis in COVID-19 Patients. Turk. J. Med. Sci. 2021, 51, 2274–2284. [Google Scholar] [CrossRef] [PubMed]
  136. Xiong, L.; Tang, H.; Xie, Q.; Fang, H.; Jing, D.; Chen, L. Immune Signatures Distinguish Pure and Mixed Sepsis in Critical COVID-19: A Retrospective Cohort Study. J. Inflamm. Res. 2025, 18, 11139–11153. [Google Scholar] [CrossRef] [PubMed]
  137. Puc, I.; Ho, T.-C.; Yen, K.-L.; Vats, A.; Tsai, J.-J.; Chen, P.-L.; Chien, Y.-W.; Lo, Y.-C.; Perng, G.C. Cytokine signature of dengue patients at different severity of the disease. Int. J. Mol. Sci. 2021, 22, 2879. [Google Scholar] [CrossRef] [PubMed]
  138. Van Ta, T.; Tran, H.T.; Ha, Q.N.T.; Nguyen, X.T.; Tran, V.K.; Simmons, C. The role of cytokines in the prognosis of children with dengue shock syndrome in Vietnam. Int. J. Res. Pharm. Sci. 2019, 10, 2519–2524. [Google Scholar] [CrossRef]
  139. Cekmez, F.; Fidanci, M.K.; Ayar, G.; Saldir, M.; Karaoglu, A.; Gündüz, R.C.; Tunc, T.; Kalkan, G. Diagnostic value of Upar, IL-33, and ST2 levels in childhood sepsis. Clin. Lab. 2016, 62, 751–755. [Google Scholar] [CrossRef] [PubMed]
  140. Halil, H.; Tayman, C.; Buyuktiryaki, M.; Okur, N.; Cakır, U.; Serkant, U. Serum interleukin-33 as a biomarker in predicting neonatal sepsis in premature infants. Comb. Chem. High Throughput Screen. 2018, 21, 510–515. [Google Scholar] [CrossRef] [PubMed]
  141. Zhang, Y.; Zhang, C.; Zhuang, R.; Ma, Y.; Zhang, Y.; Yi, J.; Yang, A.; Jin, B. IL-33/ST2 correlates with severity of haemorrhagic fever with renal syndrome and regulates the inflammatory response in Hantaan virus-infected endothelial cells. PLoS Neglected Trop. Dis. 2015, 9, e0003514. [Google Scholar] [CrossRef] [PubMed]
  142. Wang, H.; Hosakote, Y.M.; Boor, P.J.; Yang, J.; Zhang, Y.; Yu, X.; Gonzales, C.; Levine, C.B.; McLellan, S.; Cloutier, N. The alarmin IL-33 exacerbates pulmonary inflammation and immune dysfunction in SARS-CoV-2 infection. Iscience 2024, 27, 110117. [Google Scholar] [CrossRef] [PubMed]
  143. Marques, R.E.; Besnard, A.G.; Maillet, I.; Fagundes, C.T.; Souza, D.G.; Ryffel, B.; Teixeira, M.M.; Liew, F.Y.; Guabiraba, R. Interleukin-33 contributes to disease severity in Dengue virus infection in mice. Immunology 2018, 155, 477–490. [Google Scholar] [CrossRef] [PubMed]
  144. Chang, D.; Jia, J.; Zang, B. Changes in plasma interleukin-33 concentration in sepsis and its correlation with seriousness of sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2015, 27, 138–142. [Google Scholar] [PubMed]
  145. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020, 395, 1033–1034. [Google Scholar] [CrossRef] [PubMed]
  146. Waage, A.; Brandtzaeg, P.; Halstensen, A.; Kierulf, P.; Espevik, T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 1989, 169, 333–338. [Google Scholar] [CrossRef] [PubMed]
  147. Calandra, T.; Gerain, J.; Heumann, D.; Baumgartner, J.-D.; Glauser, M.P.; Group, S.-D.J.I.S. High circulating levels of interleukin-6 in patients with septic shock: Evolution during sepsis, prognostic value, and interplay with other cytokines. Am. J. Med. 1991, 91, 23–29. [Google Scholar] [CrossRef] [PubMed]
  148. Yulianto, S.; Runtunuwu, A.; Pateda, V.; Mandei, J.; Lolombulan, J. Correlation between interleukin-6 and septic shock in children. Paediatr. Indones. 2012, 52, 352–355. [Google Scholar] [CrossRef]
  149. Huang, L.; Zhao, X.; Qi, Y.; Li, H.; Ye, G.; Liu, Y.; Zhang, Y.; Gou, J. Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019. Cell. Mol. Immunol. 2020, 17, 1092–1094. [Google Scholar] [CrossRef] [PubMed]
  150. Suharti, C.; van Gorp, E.; Dolmans, W.; Setiati, T.E.; Hack, C.E.; Djokomoeljanto, R.; van der Meer, J.W. Cytokine patterns during dengue shock syndrome. Eur. Cytokine Netw. 2003, 14, 172–177. [Google Scholar] [PubMed]
  151. Juffrie, M.; Meer, G.v.; Hack, C.; Haasnoot, K.; Veerman, A.; Thijs, L. Inflammatory mediators in dengue virus infection in children: Interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. Am. J. Trop. Med. Hyg. 2001, 65, 70–75. [Google Scholar] [CrossRef] [PubMed]
  152. Grobmyer, S.R.; Lin, E.; Lowry, S.F.; Rivadeneira, D.E.; Potter, S.; Barie, P.S.; Nathan, C.F. Elevation of IL-18 in human sepsis. J. Clin. Immunol. 2000, 20, 212–215. [Google Scholar] [CrossRef] [PubMed]
  153. Oberholzer, A.; Steckholzer, U.; Kurimoto, M.; Trentz, O.; Ertel, W. Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. Shock 2001, 16, 411–414. [Google Scholar] [CrossRef] [PubMed]
  154. Valero, N.; Mosquera, J.; Torres, M.; Duran, A.; Velastegui, M.; Reyes, J.; Fernandez, M.; Fernandez, G.; Veliz, T. Increased serum ferritin and interleukin-18 levels in children with dengue. Braz. J. Microbiol. 2019, 50, 649–656. [Google Scholar] [CrossRef] [PubMed]
  155. Nasser, S.M.; Rana, A.; Doffinger, R.; Kafizas, A.; Khan, T.A.; Nasser, S. Elevated free interleukin-18 associated with severity and mortality in prospective cohort study of 206 hospitalised COVID-19 patients. Intensive Care Med. Exp. 2023, 11, 9. [Google Scholar] [CrossRef] [PubMed]
  156. Nakamura, T.; Kawagoe, Y.; Suzuki, T.; Shoji, H.; Ueda, Y.; Kobayashi, N.; Koide, H. Changes in Plasma Interleukin-18 by Direct Hemoperfusion with Polymyxin B-Immobilized Fiber in Patients with Septic Shock. Blood Purif. 2005, 23, 417–420. [Google Scholar] [CrossRef] [PubMed]
  157. Eidt, M.V.; Nunes, F.B.; Pedrazza, L.; Caeran, G.; Pellegrin, G.; Melo, D.A.S.; Possuelo, L.; Jost, R.T.; Dias, H.B.; Donadio, M.V.F.; et al. Biochemical and inflammatory aspects in patients with severe sepsis and septic shock: The predictive role of IL-18 in mortality. Clin. Chim. Acta 2016, 453, 100–106. [Google Scholar] [CrossRef] [PubMed]
  158. Mustafa, A.S.; Elbishbishi, E.A.; Agarwal, R.; Chaturvedi, U.C. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunol. Med. Microbiol. 2001, 30, 229–233. [Google Scholar] [CrossRef] [PubMed]
  159. Nanda, J.D.; Jung, C.J.; Satria, R.D.; Jhan, M.K.; Shen, T.J.; Tseng, P.C.; Wang, Y.T.; Ho, T.S.; Lin, C.F. Serum IL-18 is a potential biomarker for predicting severe dengue disease progression. J. Immunol. Res. 2021, 2021, 7652569. [Google Scholar] [CrossRef] [PubMed]
  160. Nguyen, D.N.; Huyghens, L.; Schiettecatte, J.; Smitz, J.; Vincent, J.-L. High prolactin levels are associated with more delirium in septic patients. J. Crit. Care 2016, 33, 56–61. [Google Scholar] [CrossRef] [PubMed]
  161. Dennhardt, R.; Gramm, H.J.; Meinhold, K.; Voigt, K. Patterns of endocrine secretion during sepsis. Prog. Clin. Biol. Res. 1989, 308, 751–756. [Google Scholar] [CrossRef]
  162. Asadikaram, M.; Bahrampour, S.; Rahimi Naiini, M.; Jafarzadeh, A.; Rosen, C.; Asadikaram, G. Prolactin: A Key Immunoregulator in Viral Infections and Autoimmune Diseases. Int. J. Endocrinol. 2025, 2025, 2312675. [Google Scholar] [CrossRef] [PubMed]
  163. Vardas, K.; Apostolou, K.; Psarra, K. Prolactin, cortisol and heat shock proteins in early sepsis: Preliminary data. Crit. Care 2014, 18, P234. [Google Scholar] [CrossRef]
  164. Borkowski, J.; Siemiatkowski, A.; Jedynak, M.; Czaban, S.L.; Wołczyński, S. Serum levels of luteinizing hormone, testosterone and prolactin in patients with septic shock. Prz. Lek. 2003, 60, 706–709. [Google Scholar]
  165. Ramachandra, R.N.; Sehon, A.H.; Berczi, I. Neuro-hormonal host defence in endotoxin shock. Brain Behav. Immun. 1992, 6, 157–169. [Google Scholar] [CrossRef] [PubMed]
  166. Yang, X.; Cheng, X.; Tang, Y.; Qiu, X.; Wang, Z.; Fu, G.; Wu, J.; Kang, H.; Wang, J.; Wang, H. The role of type 1 interferons in coagulation induced by gram-negative bacteria. Blood J. Am. Soc. Hematol. 2020, 135, 1087–1100. [Google Scholar] [CrossRef] [PubMed]
  167. Farkas, L. The endothelium is in shock and IFN-α/STAT1 signaling is to blame. Am. J. Respir. Cell Mol. Biol. 2021, 65, 128–129. [Google Scholar] [CrossRef] [PubMed]
  168. Karaghiosoff, M.; Steinborn, R.; Kovarik, P.; Kriegshäuser, G.; Baccarini, M.; Donabauer, B.; Reichart, U.; Kolbe, T.; Bogdan, C.; Leanderson, T.; et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 2003, 4, 471–477. [Google Scholar] [CrossRef] [PubMed]
  169. Hu, M.; Zheng, Q.; Jia, X.; Li, Y.; Dong, Y.; Wang, C.; Lin, Q.; Zhang, F.; Zhao, R.; Xu, H. Neuroprotection effect of interleukin (IL)-17 secreted by reactive astrocytes is emerged from a high-level IL-17-containing environment during acute neuroinflammation. Clin. Exp. Immunol. 2014, 175, 268–284. [Google Scholar] [CrossRef] [PubMed]
  170. Retnoningrum, D.; Mulyono, B.; Intansari, U.S.; Jaludamascena, A. Interleukin-17 as predictor mortality of septic patients: A systematic review and meta-analysis. Wiadomości Lek. 2024, 77, 1134–1140. [Google Scholar] [CrossRef] [PubMed]
  171. Jain, A.; Pandey, N.; Garg, R.; Kumar, R. IL-17 level in patients with Dengue virus infection & its association with severity of illness. J. Clin. Immunol. 2013, 33, 613–618. [Google Scholar] [CrossRef] [PubMed]
  172. Bédard-Matteau, J.; Soulé, A.; Liu, K.Y.; Fourcade, L.; Fraser, D.D.; Emad, A.; Rousseau, S. Circulating IL-17F, but not IL-17A, is elevated in severe COVID-19 and leads to an ERK1/2 and p38 MAPK-dependent increase in ICAM-1 cell surface expression and neutrophil adhesion on endothelial cells. Front. Immunol. 2024, 15, 1452788. [Google Scholar] [CrossRef] [PubMed]
  173. Maravitsa, P.; Adamopoulou, M.; Pistiki, A.; Netea, M.G.; Louis, K.; Giamarellos-Bourboulis, E.J. Systemic over-release of interleukin-17 in acute kidney injury after septic shock: Clinical and experimental evidence. Immunol. Lett. 2016, 178, 68–76. [Google Scholar] [CrossRef] [PubMed]
  174. Haque, A.; Kajiwara, C.; Matsumoto, T. IL-17A/IL-17F double KO mice are resistant to lipopolysaccharide induced endotoxic shock. Eur. Exp. Biol. 2017, 7, 14. [Google Scholar] [CrossRef]
  175. Lauw, F.N.; Simpson, A.J.; Prins, J.M.; Smith, M.D.; Kurimoto, M.; Van Deventer, S.J.; Speelman, P.; Chaowagul, W.; White, N.J.; Van Der Poll, T. Elevated plasma concentrations of interferon (ifn)-γ and the Ifn-γ—Inducing cytokines interleukin (il)-18, Il-12, and Il-15 in severe melioidosis. J. Infect. Dis. 1999, 180, 1878–1885. [Google Scholar] [CrossRef] [PubMed]
  176. Zhao, J.; Zhang, Y.; Wang, J.; Wei, B.; Liu, Y. Potential role and prognostic value of interleukin-15 for mortality among elderly patients with sepsis. J. Inflamm. Res. 2023, 16, 4481–4488. [Google Scholar] [CrossRef] [PubMed]
  177. Ueda, T.; Takeyama, Y.; Yasuda, T.; Shinzeki, M.; Sawa, H.; Nakajima, T.; Takase, K.; Matsumoto, I.; Fujita, T.; Ajiki, T.; et al. Serum interleukin-15 level is a useful predictor of the complications and mortality in severe acute pancreatitis. Surgery 2007, 142, 319–326. [Google Scholar] [CrossRef] [PubMed]
  178. Singh, A.K.; Kasarpalkar, N.; Bhowmick, S.; Paradkar, G.; Talreja, M.; Shah, K.; Tiwari, A.; Palav, H.; Kaginkar, S.; Kulkarni, R.; et al. Opposing roles for sMAdCAM and IL-15 in COVID-19 associated cellular immune pathology. J. Leukoc. Biol. 2022, 111, 1287–1295. [Google Scholar] [CrossRef] [PubMed]
  179. Patro, A.; Mohanty, S.; Prusty, B.K.; Singh, D.K.; Gaikwad, S.; Saswat, T.; Chattopadhyay, S.; Das, B.K.; Tripathy, R.; Ravindran, B. Cytokine Signature Associated with Disease Severity in Dengue. Viruses (1999–4915) 2019, 11, 34. [Google Scholar] [CrossRef] [PubMed]
  180. Bambini, K.S.; Fuentefria, A.M.; Reginatto, P. Monitoring and Detection of Cytokine Storm: A Review. Bratisl. Med. J. 2026, 127, 1327–1351. [Google Scholar] [CrossRef]
  181. Guo, Y.; Luan, L.; Patil, N.K.; Wang, J.; Bohannon, J.K.; Rabacal, W.; Fensterheim, B.A.; Hernandez, A. IL-15 Enables Septic Shock by Maintaining NK Cell Integrity and Function. J. Immunol. 2017, 198, 1320–1333. [Google Scholar] [CrossRef] [PubMed]
  182. Jiravejchakul, N.; Chan-In, W.; Thuncharoen, W.; Sungnak, W.; Charoensawan, V.; Vacharathit, V.; Matangkasombut, P. Cytokine and chemokine kinetics in natural human dengue infection as predictors of disease outcome. Sci. Rep. 2025, 15, 15612. [Google Scholar] [CrossRef] [PubMed]
  183. Pittet, J.-F.; Morel, D.R.; Hemsen, A.; Gunning, K.; Lacroix, J.-S.; Suter, P.; Lundberg, J. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann. Surg. 1991, 213, 261. [Google Scholar] [CrossRef] [PubMed]
  184. Ebihara, I.; Nakamura, T.; Shimada, N.; Shoji, H.; Koide, H. Effect of hemoperfusion with polymyxin B-immobilized fiber on plasma endothelin-1 and endothelin-1 mRNA in monocytes from patients with sepsis. Am. J. Kidney Dis. 1998, 32, 953–961. [Google Scholar] [CrossRef] [PubMed]
  185. Abraham, G.R.; Kuc, R.E.; Althage, M.; Greasley, P.J.; Ambery, P.; Maguire, J.J.; Wilkinson, I.B.; Hoole, S.P.; Cheriyan, J.; Davenport, A.P. Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. J. Mol. Cell. Cardiol. 2022, 167, 92–96. [Google Scholar] [CrossRef] [PubMed]
  186. Beishuizen, A.; Götz, J.; Kip, L.; Haanen, C.; Vermes, I. Elevated plasma levels of endothelin are associated with the severity of sepsis and presence of shock in contrast to the levels of atrial natriuretic peptide. Mediat. Inflamm. 1992, 1, 419–423. [Google Scholar] [CrossRef] [PubMed]
  187. Brauner, J.; Rohde, L.; Clausell, N. Circulating endothelin-1 and tumor necrosis factor-α: Early predictors of mortality in patients with septic shock. Intensive Care Med. 2000, 26, 305–313. [Google Scholar] [CrossRef] [PubMed]
  188. Lundberg, O.H.M.; Bergenzaun, L.; Rydén, J.; Rosenqvist, M.; Melander, O.; Chew, M.S. Adrenomedullin and endothelin-1 are associated with myocardial injury and death in septic shock patients. Crit. Care 2016, 20, 178. [Google Scholar] [CrossRef] [PubMed]
  189. Xia, A.; Li, X.; Zhao, C.; Meng, X.; Kari, G.; Wang, Y. For better or worse: Type I interferon responses in bacterial infection. Pathogens 2025, 14, 229. [Google Scholar] [CrossRef] [PubMed]
  190. Mertowska, P.; Smolak, K.; Mertowski, S.; Grywalska, E. Immunomodulatory role of interferons in viral and bacterial infections. Int. J. Mol. Sci. 2023, 24, 10115. [Google Scholar] [CrossRef] [PubMed]
  191. Hwaiz, R.; Rahman, M.; Syk, I.; Zhang, E.; Thorlacius, H. Rac1-dependent secretion of platelet-derived CCL5 regulates neutrophil recruitment via activation of alveolar macrophages in septic lung injury. J. Leukoc. Biol. 2015, 97, 975–984. [Google Scholar] [CrossRef] [PubMed]
  192. Lee, K.; Kim, H.; Park, H.S.; Kim, K.-J.; Song, H.; Shin, H.-I.; Kim, H.-S.; Seo, D.; Kook, H.; Ko, J.-H. Targeting of the osteoclastogenic RANKL–RANK axis prevents osteoporotic bone loss and soft tissue calcification in Coxsackievirus B3–infected mice. J. Immunol. 2013, 190, 1623–1630. [Google Scholar] [CrossRef] [PubMed]
  193. Bergquist, M.; Andersson, S.; Rylander, C.; Lindholm, C.; Gjertsson, I. Increased RANKL/OPG ratio and sclerostin in patients with septic shock. Clin. Microbiol. Infect. Dis. 2017, 2, 1–3. [Google Scholar] [CrossRef]
  194. Guo, Y.; Ren, M.; Ge, L.; Sun, C.; Li, R.; Ma, C.; Sui, S. Increased serum concentrations of TNF-like weak inducer of apoptosis predict higher 28-day mortality in patients with sepsis. Emerg. Med. Int. 2019, 2019, 7238705. [Google Scholar] [CrossRef] [PubMed]
  195. Nagai, M.; Hirayama, K.; Ebihara, I.; Higuchi, T.; Imaizumi, M.; Maruyama, H.; Miyamoto, Y.; Kakita, T.; Ogawa, Y.; Fujita, S. Serum TNF-related and weak inducer of apoptosis levels in septic shock patients. Ther. Apher. Dial. 2011, 15, 342–348. [Google Scholar] [CrossRef] [PubMed]
  196. Maier, S.; Emmanuilidis, K.; Entleutner, M.; Zantl, N.; Werner, M.; Pfeffer, K.; Heidecke, C.-D. Massive chemokine transcription in acute renal failure due to polymicrobial sepsis. Shock 2000, 14, 187–192. [Google Scholar] [CrossRef] [PubMed]
  197. Demoule, A.; Divangahi, M.; Yahiaoui, L.; Danialou, G.; Gvozdic, D.; Petrof, B.J. Chemokine Receptor and Ligand Upregulation in the Diaphragm during Endotoxemia and Pseudomonas Lung Infection. Mediat. Inflamm. 2009, 2009, 860565. [Google Scholar] [CrossRef] [PubMed]
  198. Salimi, V.; Ramezani, A.; Mirzaei, H.; Tahamtan, A.; Faghihloo, E.; Rezaei, F.; Naseri, M.; Bont, L.; Mokhtari-Azad, T.; Tavakoli-Yaraki, M. Evaluation of the expression level of 12/15 lipoxygenase and the related inflammatory factors (CCL5, CCL3) in respiratory syncytial virus infection in mice model. Microb. Pathog. 2017, 109, 209–213. [Google Scholar] [CrossRef] [PubMed]
  199. Tekkanat, K.K.; Maassab, H.; Miller, A.; Berlin, A.A.; Kunkel, S.L.; Lukacs, N.W. RANTES (CCL5) production during primary respiratory syncytial virus infection exacerbates airway disease. Eur. J. Immunol. 2002, 32, 3276–3284. [Google Scholar] [CrossRef] [PubMed]
  200. Zdrodowska, A.; Swierzbińska, R.; Kondrusik, M.; Pancewicz, S.A.; Zajkowska, J.M.; Grygorczuk, S.; Hermanowska-Szpakowicz, T. Cilliary neurotrophic factor in tick-borne encephalitis. Pol. Merkur. Lek. Organ Pol. Tow. Lek. 2007, 23, 100–102. [Google Scholar]
  201. Kępa, L. Evaluation of the concentration of cerebrospinal fluid ciliary neurotrophic factor (CNTF) in patients with purulent, bacterial meningitis--own observations. Prz. Epidemiol. 2012, 66, 425–430. [Google Scholar]
  202. Zuo, Y.-H.; Song, Z.-j.; Luo, Z.; Ju, M.-j.; Zhang, J. Plasma level of M-CSF was independently related to 30-day survival in patients with suspected sepsis, and correlated to pathogen load: A prospective cohort study. Inflamm. Cell Signal. 2022, 9, e1186. [Google Scholar] [CrossRef]
  203. Oren, H.; Duman, N.; MD, H.A.l.; Ozkan, H.; MD, G.l.I.r. Association between serum macrophage colony-stimulating factor levels and monocyte and thrombocyte counts in healthy, hypoxic, and septic term neonates. Pediatrics 2001, 108, 329–332. [Google Scholar] [CrossRef] [PubMed]
  204. Francois, B.; Trimoreau, F.; Vignon, P.; Fixe, P.; Praloran, V.; Gastinne, H. Thrombocytopenia in the sepsis syndrome: Role of hemophagocytosis and macrophage colony-stimulating factor. Am. J. Med. 1997, 103, 114–120. [Google Scholar] [PubMed]
  205. Wolszczak-Biedrzycka, B.; Dorf, J.; Wojewódzka-Żelezniakowicz, M.; Żendzian-Piotrowska, M.; Dymicka-Piekarska, V.; Matowicka-Karna, J.; Maciejczyk, M. Changes in chemokine and growth factor levels may be useful biomarkers for monitoring disease severity in COVID-19 patients; a pilot study. Front. Immunol. 2024, 14, 1320362. [Google Scholar] [CrossRef] [PubMed]
  206. De Jong, H.K.; Van Der Poll, T.; Wiersinga, W.J. The systemic pro-inflammatory response in sepsis. J. Innate Immun. 2010, 2, 422–430. [Google Scholar] [CrossRef] [PubMed]
  207. Dolmatova, E.V.; Wang, K.; Mandavilli, R.; Griendling, K.K. The effects of sepsis on endothelium and clinical implications. Cardiovasc. Res. 2021, 117, 60–73. [Google Scholar] [CrossRef] [PubMed]
  208. Opdenakker, G. New insights in the regulation of leukocytosis and the role played by leukocytes in septic shock. Verh.-K. Acad. Voor Geneeskd. Van. Belg. 2001, 63, 531–538. [Google Scholar]
  209. Hotchkiss, R.S.; Swanson, P.E.; Freeman, B.D.; Tinsley, K.W.; Cobb, J.P.; Matuschak, G.M.; Buchman, T.G.; Karl, I.E. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 1999, 27, 1230–1251. [Google Scholar] [CrossRef] [PubMed]
  210. Gunia, S.; Albrecht, K.; May, M.; Stosiek, P. The white pulp in the setting of the septic spleen caused by different bacteria: A comparative morphometric study. Apmis 2005, 113, 675–682. [Google Scholar] [CrossRef] [PubMed]
  211. Li, J.; Gao, X.; Liu, X.; Wu, T.; Song, H.; Gao, W.; Jia, H.; Li, Y.; Zhang, Z. The host transcriptome change involved in the inhibitory effect of exogenous interferon-γ on Getah virus replication. Front. Microbiol. 2023, 14, 1214281. [Google Scholar] [CrossRef] [PubMed]
  212. Kawamura, H.; Yago, K.; Narita, M.; Imada, T.; Nishimori, T.; Haritani, M. A fatal case in newborn piglets with Getah virus infection: Pathogenicity of the isolate. Nihon Juigaku Zasshi 1987, 49, 1003–1007. [Google Scholar] [CrossRef] [PubMed]
  213. Zhao, J.; Dellicour, S.; Yan, Z.; Veit, M.; Gill, M.S.; He, W.-T.; Zhai, X.; Ji, X.; Suchard, M.A.; Lemey, P. Early genomic surveillance and phylogeographic analysis of Getah virus, a reemerging arbovirus, in livestock in China. J. Virol. 2023, 97, e01091-01022. [Google Scholar] [CrossRef] [PubMed]
  214. Chen, H.; Ding, K.; Tang, C.; Xu, J.; Zhang, F.; Yan, Y.; Li, B.; Zhou, Y.; Yang, Y.; Yang, H. Chikungunya virus drives gut microbiota shifts and IFN-Mediated intestinal repair: Insights into microbiota-immune interplay. Gut Microbes 2025, 17, 2512900. [Google Scholar] [CrossRef] [PubMed]
  215. Keely, S.J.; Barrett, K.E. Intestinal secretory mechanisms and diarrhea. Am. J. Physiol.-Gastrointest. Liver Physiol. 2022, 322, G405–G420. [Google Scholar] [CrossRef] [PubMed]
  216. Kreydiyyeh, S.I.; Al-Sadi, R. Interleukin-1 β Increases urine flow rate and inhibits protein expression of na+/K+-ATPase in the rat jejunum and kidney. J. Interferon Cytokine Res. 2002, 22, 1041–1048. [Google Scholar] [CrossRef] [PubMed]
  217. Schmitz, H.; Fromm, M.; Bode, H.; Scholz, P.; Riecken, E.; Schulzke, J. Tumor necrosis factor-alpha induces Cl-and K+ secretion in human distal colon driven by prostaglandin E2. Am. J. Physiol.-Gastrointest. Liver Physiol. 1996, 271, G669–G674. [Google Scholar] [CrossRef] [PubMed]
  218. Rocha, F.; Musch, M.W.; Lishanskiy, L.; Bookstein, C.; Sugi, K.; Xie, Y.; Chang, E.B. IFN-γ downregulates expression of Na+/H+ exchangers NHE2 and NHE3 in rat intestine and human Caco-2/bbe cells. Am. J. Physiol.-Cell Physiol. 2001, 280, C1224–C1232. [Google Scholar] [CrossRef] [PubMed]
  219. Dejager, L.; Vandevyver, S.; Ballegeer, M.; Van Wonterghem, E.; An, L.-L.; Riggs, J.; Kolbeck, R.; Libert, C. Pharmacological inhibition of type I interferon signaling protects mice against lethal sepsis. J. Infect. Dis. 2014, 209, 960–970. [Google Scholar] [CrossRef] [PubMed]
  220. Nansen, A.; Randrup Thomsen, A. Viral Infection Causes Rapid Sensitization to Lipopolysaccharide: Central Role of IFN-αβ. J. Immunol. 2001, 166, 982–988. [Google Scholar] [CrossRef] [PubMed]
  221. Howe, M.; Bauer, J.; Schulze, A.; Kropp, S.; Locksley, R.M.; Alferink, J.; Weighardt, H.; Scheu, S. Production of IFNβ by Conventional Dendritic Cells after Stimulation with Viral Compounds and IFNβ-Independent IFNAR1-Signaling Pathways are Associated with Aggravation of Polymicrobial Sepsis. Int. J. Mol. Sci. 2019, 20, 4410. [Google Scholar] [CrossRef] [PubMed]
  222. Pinto, A.K.; Ramos, H.J.; Wu, X.; Aggarwal, S.; Shrestha, B.; Gorman, M.; Kim, K.Y.; Suthar, M.S.; Atkinson, J.P.; Gale, M., Jr. Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis. PLoS Pathog. 2014, 10, e1004086. [Google Scholar] [CrossRef] [PubMed]
  223. Zhao, M.; Ji, L.; Zhao, Y.; Yang, S.; Yang, H.; He, B.; Wang, S.; Zhang, W. Getah virus non-structural protein 2 inhibits type I interferon production by preventing K63-linked polyubiquitination of IKKε and causing widespread cellular shutoff. Microbiol. Spectr. 2026, 14, e03419-03425. [Google Scholar] [CrossRef] [PubMed]
  224. Taylor, M.M.; Roberts, R.W.; Rayner, J.O. CHIKV-Infected Human Dermal Fibroblasts Mount an IFNβ Transcriptional Response Independent of TBK1/IKKε Signaling That Fails to Prevent Lethal Infection. Viruses 2026, 18, 503. [Google Scholar] [CrossRef] [PubMed]
  225. Mostafavi, H.; Abeyratne, E.; Zaid, A.; Taylor, A. Arthritogenic Alphavirus-Induced Immunopathology and Targeting Host Inflammation as A Therapeutic Strategy for Alphaviral Disease. Viruses 2019, 11, 290. [Google Scholar] [CrossRef] [PubMed]
  226. Hean Tang, P.C.; Hann Ng, W.; Liu, X. Host immune responses to arthritogenic alphavirus infection, with emphasis on type I IFN responses. Zoonoses 2022, 2, 972. [Google Scholar] [CrossRef]
  227. Nguyen, B.H.; Troisi, E.; Griffin, D.E. Interferon Regulatory Factor 7-mediated induction of interferon-α is required for survival from alphavirus encephalomyelitis. J. Immunol. 2023, 210, 75.35. [Google Scholar] [CrossRef]
  228. Hata, N.; Sato, M.; Takaoka, A.; Asagiri, M.; Tanaka, N.; Taniguchi, T. Constitutive IFN-α/β signal for efficient IFN-α/β gene induction by virus. Biochem. Biophys. Res. Commun. 2001, 285, 518–525. [Google Scholar] [CrossRef] [PubMed]
  229. Barchet, W.; Cella, M.; Odermatt, B.; Asselin-Paturel, C.; Colonna, M.; Kalinke, U. Virus-induced interferon α production by a dendritic cell subset in the absence of feedback signaling in vivo. J. Exp. Med. 2002, 195, 507–516. [Google Scholar] [CrossRef] [PubMed]
  230. Kochs, G.; Anzaghe, M.; Kronhart, S.; Wagner, V.; Gogesch, P.; Scheu, S.; Lienenklaus, S.; Waibler, Z. In vivo conditions enable IFNAR-independent type I interferon production by peritoneal CD11b+ cells upon Thogoto virus infection. J. Virol. 2016, 90, 9330–9337. [Google Scholar] [CrossRef] [PubMed]
  231. Anzaghe, M.; Kronhart, S.; Niles, M.A.; Höcker, L.; Dominguez, M.; Kochs, G.; Waibler, Z. Type I interferon receptor-independent interferon-α induction upon infection with a variety of negative-strand RNA viruses. J. General. Virol. 2021, 102, 001616. [Google Scholar] [CrossRef] [PubMed]
  232. Asano, A. Host Cell-Intrinsic Antiviral Defense Induced by Type I Interferons. Korean J. Agric. Sci. 2008, 35, 177–182. [Google Scholar]
  233. Voigt, E.A.; Swick, A.; Yin, J. Rapid induction and persistence of paracrine-induced cellular antiviral states arrest viral infection spread in A549 cells. Virology 2016, 496, 59–66. [Google Scholar] [CrossRef] [PubMed]
  234. van den Pol, A.N.; Ding, S.; Robek, M.D. Long-distance interferon signaling within the brain blocks virus spread. J. Virol. 2014, 88, 3695–3704. [Google Scholar] [CrossRef] [PubMed]
  235. Efa, B.B.; Antwi-Osei Jnr, J. Can a mosquito-borne virus become a cancer therapy? rethinking Getah virus through the lens of oncolytic virotherapy. Front. Cell. Infect. Microbiol. 2026, 16, 1768174. [Google Scholar] [CrossRef] [PubMed]
  236. Wollmann, G.; Robek, M.D.; van den Pol, A.N. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J. Virol. 2007, 81, 1479–1491. [Google Scholar] [CrossRef] [PubMed]
  237. Jain, J.; Narayanan, V.; Kumar, A.; Shrinet, J.; Srivastava, P.; Chaturvedi, S.; Sunil, S. Establishment and comparison of pathogenicity and related neurotropism in two age groups of immune competent mice, C57BL/6J using an Indian isolate of chikungunya virus (CHIKV). Viruses 2019, 11, 578. [Google Scholar] [CrossRef] [PubMed]
  238. Conabady, E.; Vernochet, C.; Gulmez, A.; Marti, F.; Faure, P.; Parnaudeau, S.; Tronche, F. Social hierarchy and behavioral individuality in colonies of isogenic female mice. bioRxiv 2025. [Google Scholar] [CrossRef]
  239. Horii, Y.; Nagasawa, T.; Sakakibara, H.; Takahashi, A.; Tanave, A.; Matsumoto, Y.; Nagayama, H.; Yoshimi, K.; Yasuda, M.T.; Shimoi, K. Hierarchy in the home cage affects behaviour and gene expression in group-housed C57BL/6 male mice. Sci. Rep. 2017, 7, 6991. [Google Scholar] [CrossRef] [PubMed]
  240. Williamson, C.M.; Lee, W.; DeCasien, A.R.; Lanham, A.; Romeo, R.D.; Curley, J.P. Social hierarchy position in female mice is associated with plasma corticosterone levels and hypothalamic gene expression. Sci. Rep. 2019, 9, 7324. [Google Scholar] [CrossRef] [PubMed]
  241. Quatrini, L.; Wieduwild, E.; Escaliere, B.; Filtjens, J.; Chasson, L.; Laprie, C.; Vivier, E.; Ugolini, S. Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells. Nat. Immunol. 2018, 19, 954–962. [Google Scholar] [CrossRef] [PubMed]
  242. Stark, D.L.; Cauceglia, J.W.; Sitzman, V.N.; Repetto, M.C.; Tadje, J.M.; Potts, W.K. Friend virus severity is associated with male mouse social status and environmental temperature. Anim. Behav. 2022, 187, 221–231. [Google Scholar] [CrossRef] [PubMed]
  243. Vialard, F.; Olivier, M. Thermoneutrality and Immunity: How Does Cold Stress Affect Disease? Front. Immunol. 2020, 11, 588387. [Google Scholar] [CrossRef] [PubMed]
  244. Prow, N.A.; Tang, B.; Gardner, J.; Le, T.T.; Taylor, A.; Poo, Y.S.; Nakayama, E.; Hirata, T.D.; Nakaya, H.I.; Slonchak, A. Lower temperatures reduce type I interferon activity and promote alphaviral arthritis. PLoS Pathog. 2017, 13, e1006788. [Google Scholar] [CrossRef] [PubMed]
  245. Maher, R.L.; Barbash, S.M.; Lynch, D.V.; Swoap, S.J. Group housing and nest building only slightly ameliorate the cold stress of typical housing in female C57BL/6J mice. Am. J. Physiol.-Regul. Integr. Comp. Physiol. 2015, 308, R1070–R1079. [Google Scholar] [CrossRef] [PubMed]
  246. Landen, J.G.; Vandendoren, M.; Killmer, S.; Bedford, N.L.; Nelson, A.C. Huddling substates in mice facilitate dynamic changes in body temperature and are modulated by Shank3b and Trpm8 mutation. Commun. Biol. 2024, 7, 1186. [Google Scholar] [CrossRef] [PubMed]
  247. Zepeda, J.A.; Bautista, A.; Rangassamy, M.; Monclus, R.; Bocquet, C.; Martínez-Gómez, M.; Gouat, P.; Feron, C.; Hudson, R.; Rödel, H.G. Individual differences in early body mass affect thermogenic performance and sibling interactions in litter huddles of the house mouse. Dev. Psychobiol. 2018, 60, 825–835. [Google Scholar] [CrossRef] [PubMed]
  248. Mata, F.; Araújo, J.; Kowalczky, A.; Cerqueira, J. The effect of litter hierarchy and teat allocation on suckling piglets’ growth. Arch. Anim. Breed. 2025, 68, 263–269. [Google Scholar] [CrossRef] [PubMed]
  249. Lessard, M.; Blais, M.; Beaudoin, F.; Deschene, K.; Verso, L.L.; Bissonnette, N.; Lauzon, K.; Guay, F. Piglet weight gain during the first two weeks of lactation influences the immune system development. Vet. Immunol. Immunopathol. 2018, 206, 25–34. [Google Scholar] [CrossRef] [PubMed]
  250. Graham, V.A.; Easterbrook, L.; Rayner, E.; Findlay-Wilson, S.; Flett, L.; Kennedy, E.; Fotheringham, S.; Kempster, S.; Almond, N.; Dowall, S. Comparison of chikungunya virus-induced disease progression and pathogenesis in type-i interferon receptor-deficient mice (A129) and two wild-type (129Sv/Ev and C57BL/6) mouse strains. Viruses 2024, 16, 1534. [Google Scholar] [CrossRef] [PubMed]
Figure 1. GETV infection of Ifnar1-/- mice. Ifnar1-/- mice (males 11–12 weeks of age) were infected subcutaneously in the hind feet with GETV (2 × 104 CCID50 per mouse). When mice reached or approached ethically defined endpoints (primarily weight loss ≈ 20%) they were euthanized (†). Control mice were inoculated with heat inactivated GETV and were euthanized at the same time to provide time matched controls. (a) Mice were weighed daily and weight change relative to day 0 plotted for each mouse. (b) Serum viremias for the individual mice described in a. Detection limit ≈ 2 log10CCID50/mL of serum (dotted line); ND—not detected. (c) Percent change in haematocrit relative to Controls at euthanasia. Three out of five GETV infected mice showed significantly increased haematocrit over Controls. Statistics by Kolmogorov-Smirnov exact test comparing 3 GETV infected mice (black box) with the 5 Controls.
Figure 1. GETV infection of Ifnar1-/- mice. Ifnar1-/- mice (males 11–12 weeks of age) were infected subcutaneously in the hind feet with GETV (2 × 104 CCID50 per mouse). When mice reached or approached ethically defined endpoints (primarily weight loss ≈ 20%) they were euthanized (†). Control mice were inoculated with heat inactivated GETV and were euthanized at the same time to provide time matched controls. (a) Mice were weighed daily and weight change relative to day 0 plotted for each mouse. (b) Serum viremias for the individual mice described in a. Detection limit ≈ 2 log10CCID50/mL of serum (dotted line); ND—not detected. (c) Percent change in haematocrit relative to Controls at euthanasia. Three out of five GETV infected mice showed significantly increased haematocrit over Controls. Statistics by Kolmogorov-Smirnov exact test comparing 3 GETV infected mice (black box) with the 5 Controls.
Preprints 230369 g001
Figure 2. Mouse intestines. Ifnar1-/- mice described in Figure 1 were euthanized on day 3/4 after inoculation with heat inactivated GETV (Control) or 3/4 days post infection with live GETV. Intestines were dissected out and photographed. Faecal material (dark brown) is clearly visible in the small intestine (yellow arrows), cecum (orange arrows), and colon (white arrows) of Control animals.
Figure 2. Mouse intestines. Ifnar1-/- mice described in Figure 1 were euthanized on day 3/4 after inoculation with heat inactivated GETV (Control) or 3/4 days post infection with live GETV. Intestines were dissected out and photographed. Faecal material (dark brown) is clearly visible in the small intestine (yellow arrows), cecum (orange arrows), and colon (white arrows) of Control animals.
Preprints 230369 g002
Figure 3. Splenomegaly in GETV infected Ifnar1-/- mice. (a) Mice were euthanized on day 3/4 post infection with live GETV (top row, n = 4), with Control mice euthanized at the same time points (bottom row, n = 4) (mice described in Figure S1). Spleens were removed, fixed in paraffin and longitudinal median sections stained using H&E. (b) The areas of the stained sections were determined using Aperio ImageScope (Annotation window and pen tool). Statistics by Kolmogorov Smirnov exact test.
Figure 3. Splenomegaly in GETV infected Ifnar1-/- mice. (a) Mice were euthanized on day 3/4 post infection with live GETV (top row, n = 4), with Control mice euthanized at the same time points (bottom row, n = 4) (mice described in Figure S1). Spleens were removed, fixed in paraffin and longitudinal median sections stained using H&E. (b) The areas of the stained sections were determined using Aperio ImageScope (Annotation window and pen tool). Statistics by Kolmogorov Smirnov exact test.
Preprints 230369 g003
Figure 4. Histopathological features of GETV infected Ifnar1-/- mice. (These mice are described in Figure S1 and were euthanized when they reached ethically defined endpoints). (a) Lungs showed blood vessel wall damage with leakage (white oval), leukostasis (white arrowheads), fibrinous pleurisy (black rectangle), and fibrin deposits in alveoli (black arrow). (b) Spleens showed areas of focal necrosis (white oval), cells undergoing degeneration (white arrows). (c) Liver displayed leukocytosis (white ovals) and leukostasis (black arrowheads). (d) Brains showed mild focal inflammatory cell infiltration in meninges (black arrowheads).
Figure 4. Histopathological features of GETV infected Ifnar1-/- mice. (These mice are described in Figure S1 and were euthanized when they reached ethically defined endpoints). (a) Lungs showed blood vessel wall damage with leakage (white oval), leukostasis (white arrowheads), fibrinous pleurisy (black rectangle), and fibrin deposits in alveoli (black arrow). (b) Spleens showed areas of focal necrosis (white oval), cells undergoing degeneration (white arrows). (c) Liver displayed leukocytosis (white ovals) and leukostasis (black arrowheads). (d) Brains showed mild focal inflammatory cell infiltration in meninges (black arrowheads).
Preprints 230369 g004
Figure 5. RNA-Seq analysis and summary of IPA bioinformatic output. (a) GETV read counts for GETV infected mice and Control mice that were inoculated with heat inactivated GETV (the same mice as shown in Figure 1, with 1 control mouse excluded due to poor RNA quality). Mean and SE are also shown. Statistics by Kolmogorov-Smirnov exact test. (b) Principal Component Analysis plot. (c) Visualization of differential gene expression by volcano plot (GETV infected vs. Control). (d) Summary of IPA analyses of 2383 DEGs, top scoring annotations are boxed into themes. USR—Up-Stream Regulator. (Full data set is provided in Table S1).
Figure 5. RNA-Seq analysis and summary of IPA bioinformatic output. (a) GETV read counts for GETV infected mice and Control mice that were inoculated with heat inactivated GETV (the same mice as shown in Figure 1, with 1 control mouse excluded due to poor RNA quality). Mean and SE are also shown. Statistics by Kolmogorov-Smirnov exact test. (b) Principal Component Analysis plot. (c) Visualization of differential gene expression by volcano plot (GETV infected vs. Control). (d) Summary of IPA analyses of 2383 DEGs, top scoring annotations are boxed into themes. USR—Up-Stream Regulator. (Full data set is provided in Table S1).
Preprints 230369 g005
Table 1. The association of the top cytokine/chemokine USRs (Activation z score > 4, Table S1, Cytokine USRs) with references reporting elevated levels of the same cytokine/chemokine in sepsis and/or septic shock. Sepsis/septic shock association with bacterial or viral, or bacterial and viral (Both). (—) no literature found specifically associating elevated levels of the indicated cytokine/chemokine with sepsis/septic shock; nevertheless, elevated levels of the cytokine/chemokine may be associated with infections. Elevated levels of cytokines/chemokines determined by measuring protein and/or RNA levels. Literature searches were undertaken with the help of Elicit (Elicit Research, PBC, Oakland, CA, USA), confirmed using Google Scholar, with manuscript downloads via the University of Queensland Library.
Table 1. The association of the top cytokine/chemokine USRs (Activation z score > 4, Table S1, Cytokine USRs) with references reporting elevated levels of the same cytokine/chemokine in sepsis and/or septic shock. Sepsis/septic shock association with bacterial or viral, or bacterial and viral (Both). (—) no literature found specifically associating elevated levels of the indicated cytokine/chemokine with sepsis/septic shock; nevertheless, elevated levels of the cytokine/chemokine may be associated with infections. Elevated levels of cytokines/chemokines determined by measuring protein and/or RNA levels. Literature searches were undertaken with the help of Elicit (Elicit Research, PBC, Oakland, CA, USA), confirmed using Google Scholar, with manuscript downloads via the University of Queensland Library.
Regulator z-Score Sepsis
Association
Sepsis References Septic Shock
Association
Septic Shock References
IFNG 9.82 Both [98,99,100] Both [98,101,102,103,104]
IL1B 8.81 Both [99,105,106]. Dengue virus infected Ifnar1-/- mice [107] Both [98,108,109,110,111,112]
TNF 8.59 Both [98,99] Both [98,113,114,115,116]
IL1A 7.52 Both [117,118]. Signature similar to IL-1B - Similar to IL-1B
CSF2
(GM-CSF)
6.63 Both [119,120,121,122,123] Both [124,125]
IL5 6.47 Both [126,127]. Severe infections [128]
OSM 6.37 Both [129,130,131] Bacterial [132]
IL21 6.29 Viral [133,134]. Severe COVID-19 [135]
IL2 5.97 Both [136,137] Both [116,138]
IL33 5.92 Both [139,140,141,142,143] Bacterial [144]
IL6 5.89 Both [99,145] Both [146,147,148,149,150,151]
IL18 5.60 Both [152,153,154,155] Both [156,157,158,159]
PRL Prolactin 5.53 Both [160,161,162] Bacterial [163,164,165]
IFNA2/A4 5.44/4.62 Both [166] (Not IFNα subtype specific) Both [167,168] (Not IFNα subtype specific)
IL17A 5.11 Both [169,170,171,172] Bacterial [173,174]. Severe dengue [171]
IL15 4.94 Bacterial [175,176,177]. Virus infection [178,179,180] Bacterial [122,181]. Dengue haemorrhagic fever [182]
EDN1
Endothelin-1
4.91 Both [183,184]. Severe viral [185] Bacterial [186,187,188]
IFNB1 4.88 Viral and bacterial infections [189,190]
TNFSF11 (RANKL) 4.83 Bacterial [191]. Virus infection [192] Bacterial Higher sRANKL/OPG ratio [193]
TNFSF12 (TWEAK) 4.60 Both [194,195] Bacterial [195]
CCL5 (RANTES) 4.57 Bacterial [191,196,197].
Virus infections [198,199]
CNTF Ciliary neurotrophic factor 4.56 Viral and bacterial infections [200,201]
CSF1 (M-CSF) 4.20 Bacterial [202,203,204]. Virus infections [205]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.